ondansetron has been researched along with Benign Neoplasms in 193 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We assessed the efficacy of aprepitant (APR) or 10 or 5 mg OLN (OLN10 or OLN5) plus ondansetron and dexamethasone for chemotherapy-induced nausea/vomiting (CINV) prophylaxis in patients receiving high-emetogenic chemotherapy (HEC)." | 9.34 | Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy. ( Akewanlop, C; Danchaivijitr, P; Ithimakin, S; Korphaisarn, K; Laocharoenkiat, A; Nimmannit, A; Soparattanapaisarn, N; Techawattanawanna, S; Theeratrakul, P, 2020) |
| "The purpose of the study was to compare efficacy and toxicity of olanzapine (OLN; a higher-cost drug) and haloperidol (HAL; a lower-cost drug) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients who receive highly emetogenic chemotherapy (HEC)." | 9.30 | Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal. ( Acharya, B; Dulal, S; Neupane, P; Paudel, BD; Poudyal, BS; Shah, A; Shilpakar, R; Wood, LA, 2019) |
| "Palonosetron is non-inferior and cost-effective compared to ondansetron for prevention of acute chemotherapy-induced vomiting (CIV) in children receiving moderate and high emetogenic chemotherapy." | 9.27 | A randomized, open-label non-inferiority study to compare palonosetron and ondansetron for prevention of acute chemotherapy-induced vomiting in children with cancer receiving moderate or high emetogenic chemotherapy. ( Jain, S; Kapoor, G; Koneru, S; Vishwakarma, G, 2018) |
| "Subjects aged 6 months to 17 years scheduled to receive chemotherapeutic agents associated with at least moderate risk for emesis were randomly assigned to receive either aprepitant plus ondansetron (aprepitant regimen) or placebo plus ondansetron (control regimen); both could be administered with or without dexamethasone." | 9.27 | Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in paediatric subjects: An analysis by age group. ( DiCristina, C; Green, S; Kang, HJ; Loftus, S; Pong, A; Zwaan, CM, 2018) |
| "This study evaluated the efficacy and safety of a 3-day aprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting (CINV) during the first cycle of non-anthracycline plus cyclophosphamide (AC)-based moderately emetogenic chemotherapy (MEC) based on government guidelines in Korean patients." | 9.24 | Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. ( Ahn, MJ; Cho, CH; Cho, EK; Jang, JS; Jung, H; Kim, DJ; Kim, JE; Kim, JW; Lee, KY; Lee, MA; Lim, MC; Min, KW; Sung, YL; Sym, SJ, 2017) |
| "Palonosetron has shown efficacy in the prevention of chemotherapy-induced nausea and vomiting in adults undergoing moderately or highly emetogenic chemotherapy." | 9.22 | Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study. ( Basharova, EV; Kabickova, E; Kovács, G; Nicolas, P; Spinelli, T; Wachtel, AE, 2016) |
| "Significantly more patients receiving rolapitant than control reported no emesis or interfering nausea (combined measure) in cycles 2 (p = 0." | 9.22 | Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. ( Arora, S; Chasen, M; Navari, R; Powers, D; Rapoport, B; Schnadig, I; Schwartzberg, L, 2016) |
| "To observe the therapeutic efficacy of Hewei Zhiou Recipe (HZR) combined ondansetron hydrochloride (OH) in treating vomiting in children patients with solid tumor." | 9.16 | [Treatment of vomiting in children patients with solid tumor by hewei zhiou recipe combined ondansetron hydrochloride]. ( Liu, ZM; Shi, X; Zhu, XD, 2012) |
| "All doses of oral casopitant as a 3-day regimen (and likely as a 150-mg single oral dose) in combination with Ond/Dex provided significant improvement in the prevention of cisplatin-induced emesis." | 9.14 | Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting. ( Bandekar, RR; Dediu, M; Grunberg, SM; Ramlau, R; Roila, F; Rolski, J; Russo, MW, 2009) |
| "Aprepitant was shown previously to be effective for prevention of chemotherapy-induced nausea and vomiting (CINV) with moderately emetogenic chemotherapy (MEC) in breast cancer patients receiving an anthracycline and cyclophosphamide (AC)-based regimen." | 9.14 | Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. ( Boice, JA; Brown, C; Carides, A; Hardwick, JS; Jordan, K; Rapoport, BL; Schmoll, HJ; Taylor, A; Webb, T, 2010) |
| "The purpose of this phase III trial was to evaluate the efficacy and safety of regimens containing casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting during the first cycle in patients receiving moderately emetogenic chemotherapy (MEC)." | 9.14 | Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. ( Apornwirat, W; Aziz, Z; Grunberg, SM; Guckert, M; Herrstedt, J; Levin, J; Ranganathan, S; Roila, F; Russo, MW; Shaharyar, A; Van Belle, S, 2009) |
| " This randomized, double-blind, double-dummy, multicenter study was designed to compare the efficacy and tolerance of metopimazine and ondansetron at preventing nausea and emesis in patients receiving chemotherapy." | 9.12 | A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis. ( Bensaoula, O; Bethune-Volters, A; Chidiac, J; Delgado, A; Di Palma, M; Khamales, S, 2006) |
| "To compare the efficacy and tolerability of dronabinol, ondansetron, or the combination for delayed chemotherapy-induced nausea and vomiting (CINV) in a 5-day, double-blind, placebo-controlled study." | 9.12 | Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. ( Baranowski, V; Barbato, LM; Carter, FJ; Jhangiani, H; Meiri, E; Vredenburgh, JJ; Yang, HM, 2007) |
| "In low dose cisplatin regimen, complete suppression of delayed emesis occurred in 55 per cent patients receiving ondansetron and in 30 per cent patients receiving metoclopramide." | 9.11 | Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis. ( Bhatia, A; Sharma, M; Tripathi, KD, 2004) |
| "To compare the efficacy and tolerability of associations of metopimazine and ondansetron with methylprednisolone for the prevention of delayed chemotherapy-induced nausea and emesis." | 9.11 | Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy. ( Bloch, J; Delgado, A; Khayat, D; Meric, JB; Rixe, O, 2005) |
| "When it was added to a standard regimen of intravenous ondansetron and oral dexamethasone in the current study, aprepitant reduced chemotherapy-induced nausea and vomiting and was generally well tolerated, although increases in infection were noted that were assumed to be due to elevated dexamethasone levels as a result of the pharmacokinetic interaction." | 9.10 | Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. ( Carides, AD; Chawla, SP; Elmer, ME; Evans, JK; Gralla, RJ; Grunberg, SM; Hesketh, PJ; Horgan, KJ; Rittenberg, C; Schmidt, C; Taylor, A, 2003) |
| " The present study aimed to study the efficacy and tolerability of ondansetron versus (vs) metoclopramide in different dose related grades of cisplatin induced acute emesis." | 9.10 | Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy. ( Bhatia, A; Sharma, M; Tripathi, KD, 2003) |
| ") ondansetron with oral syrup ondansetron plus oral dexamethasone in the prevention of nausea and emesis in pediatric patients receiving moderately/highly emetogenic chemotherapy." | 9.09 | A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherap ( Breatnach, F; Daly, SA; Haigh, C; Hung, IJ; Kowalczyk, J; Leal, C; McKenna, CJ; Mitchell, T; Ninane, J; Smelhaus, V; White, L; Zhestkova, N, 2000) |
| "The antiemetic effect of ondansetron (Supplied by Qi Lu Pharmaceutical Company) in cisplatin-induced nausea and vomiting was studied in a randomized cross-over trial in 167 patients." | 9.08 | [The role of ondansetron (qi lu) in the prevention of cisplatin-induced vomiting--a randomized clinical trial]. ( Zeng, W; Zhang, P; Zhou, J, 1995) |
| "To compare the efficacy and safety of granisetron and ondansetron, serotonin (5-HT3) receptor antagonists shown to be effective in the prevention of chemotherapy-induced emesis." | 9.08 | Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. ( Fitts, D; Friedman, C; Gandara, D; Hall, S; Hesketh, P; Mailliard, J; Navari, R; Ritter, H, 1995) |
| "The aim of the study was to compare granisetron (GRA) with ondansetron (OND) in the prevention of acute emesis in consecutive chemotherapy-naive patients admitted to our department to receive a cytotoxic treatment containing cisplatinum (CP) at a dose > or = 50 mg/m2." | 9.08 | An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens. ( Angelelli, B; Guaraldi, M; Martoni, A; Pannuti, F; Strocchi, E, 1996) |
| "To assess the comparative antiemetic efficacy of single-dose intravenous (IV) dolasetron mesylate and ondansetron in preventing cisplatin-induced nausea and vomiting." | 9.08 | Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis P ( Anthony, L; Benedict, C; Gralla, R; Grote, T; Hahne, W; Hainsworth, J; Hesketh, P; Khojasteh, A; Kris, M; Navari, R; Tapazoglou, E, 1996) |
| "In contrast to the broad experience concerning the therapeutic use of carboplatin, only limited data are available regarding the patterns of carboplatin-induced emesis, one of its most distressing side effects." | 9.08 | Pattern of carboplatin-induced emesis. The German Ondansetron Study Group. ( Cramer-Giraud, U; du Bois, A; Fiola, M; Glaubitz, M; Thomssen, C; Vach, W, 1995) |
| "The purpose of this study was to investigate the efficacy and safety of oral ondansetron, given alone or in combination with dexamethasone in the control of cisplatin-induced delayed emesis." | 9.08 | A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. ( Depierre, A; Goedhals, L; McQuade, B; McRae, J; Olver, I; Paska, W; Seitz, JF; Stewart, DJ; Wilkinson, JR, 1996) |
| "The efficacy and safety of ondansetron 8 mg BID compared with 8 mg TID for 3 days in the prevention of nausea and vomiting in 402 patients on cyclophosphamide (> or = 500 mg/m2)-based chemotherapy were evaluated in a multicenter, randomized, double-blind, stratified study." | 9.08 | Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group. ( Beck, TM; Chang, A; Griffin, D; Harvey, WH; Meshad, M; Navari, R; Wentz, A; York, M, 1997) |
| "The antiemetic efficacy of ondansetron and dexamethasone (Ondex) was randomly compared to that of high-dose metoclopramide, dexamethasone, and orphenadrine (Control) in the prevention of emesis induced by cyclophosphamide-doxorubicin chemotherapy in 64 chemotherapy-naive breast cancer patients." | 9.07 | Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses ( Campora, E; Giudici, S; Merlini, L; Rosso, R; Rubagotti, A, 1994) |
| "This study compares the efficacy and safety of ondansetron alone with that of ondansetron plus dexamethasone in the prevention of emesis induced by high-dose cisplatin (> or = 100 mg/m2)." | 9.07 | A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. ( Beck, TM; Bricker, LJ; Hainsworth, JD; Haley, B; Harker, WG; Harvey, WH; Hesketh, PJ; Kish, JA; Murphy, WK; Ryan, T, 1994) |
| "One-hundred and forty-five chemotherapy patients receiving cisplatin- and non-cisplatin-containing regimens participated in an open evaluation of ondansetron, a 5-HT3 receptor antagonist, in the prophylaxis of acute and delayed nausea and vomiting." | 9.07 | Ondansetron in the treatment of nausea and vomiting induced by chemotherapy. Portuguese Ondansetron Study Group. ( Batarda, M; Brandão, A; de Faria, L; de Matos, E; dos Reis, F; Fráguas, A; Ribeiro, I; Ribeiro, M; Ribiero, MM; Uva, S, 1993) |
| "We evaluated the efficacy and safety of oral ondansetron, a selective antagonist of 5-HT3 receptors, for the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapy (> 500 mg/m2)." | 9.07 | Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group. ( Burton, G; Ciociola, AA; Cubeddu, LX; Galvin, D; Meshad, M; Pendergrass, K; Ryan, T; York, M, 1994) |
| "To compare the effectiveness and side effects of antiemetic regimens using ondansetron alone (O) versus ondansetron plus dexamethasone (OD) versus ondansetron plus dexamethasone plus lorazepam (ODA) in the prevention of emesis induced by cisplatin-based chemotherapy." | 9.07 | A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy. ( Ahn, MJ; Choi, SS; Kim, SH; Lee, JS; Lee, KH; Suh, C, 1994) |
| "One hundred cancer patients receiving non-cisplatin containing chemotherapy were entered in a prospective study in which the efficacy of ondansetron was compared with standard antiemetic treatments in the prophylaxis of nausea and emesis." | 9.07 | Comparison of ondansetron with customary treatment in the prophylaxis of nausea and emesis induced by non-cisplatin containing chemotherapy. ( Flander, MK; Heikkinen, MI; Jantunen, IT; Kataja, VV; Kuoppala, TA; Teerenhovi, L, 1993) |
| "A total of 535 chemotherapy naive, hospitalised patients (263 male/272 female) scheduled to receive cisplatin (50-120 mg m-2)-containing regimens participated in a randomised, double-blind, parallel group study to evaluate the efficacy and safety of three intravenous dose schedules of ondansetron in the prophylaxis of acute nausea and emesis." | 9.07 | Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Stu ( Buser, K; Christmann, D; Kitchener, H; Paes, D; Porteder, H; Schmidt, M; Schuller, J; Sevelda, P; Seynaeve, C; Van Belle, S, 1992) |
| "The anti-emetic effect, safety and clinical usefulness of ondansetron for the treatment of nausea and vomiting caused by anticancer drugs including cisplatin, was evaluated by a multi-institutional study in patients with various malignancies." | 9.07 | [Evaluation of SN-307 (ondansetron), given intravenously for the treatment of nausea and vomiting caused by anticancer drugs including cisplatin-open study]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Clinical usefulness of ondansetron as an antiemetic for the treatment of nausea and vomiting induced by anticancer drugs including cisplatin (> or = 50 mg/m2) was evaluated by a multi-institutional, double-blind comparative study with placebo with inpatients with various malignancies." | 9.07 | [Evaluation of SN-307 (ondansetron), given intravenously in the treatment of nausea and vomiting caused by anticancer drugs including cisplatin--a placebo-controlled, double-blind comparative study]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "The selective 5-hydroxytryptamine3 antagonist ondansetron has been shown to be effective in preventing nausea and vomiting associated with highly emetogenic cisplatin chemotherapy." | 9.07 | Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials. ( Beck, TM, 1992) |
| "In an open, drug-oriented phase-II/III-study 24 patients were treated with the 5-HT3-antagonist Ondansetron as an antiemetic drug for chemotherapy-induced nausea and emesis." | 9.06 | [Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study]. ( Berdel, WE; Ertl, A; Fink, U; Perker, M; Reichold, M; Serve, H, 1990) |
| " Ondansetron exhibited similar efficacy than granisetron and tropisetron, as well as greater efficacy than dolasetron for acute vomiting." | 8.93 | Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis. ( Acúrcio, Fde A; Andrade, EI; Cherchiglia, ML; De Araújo, VE; Marra, LP; Reis, IA; Simino, GP, 2016) |
| "Despite the advance in supportive care that occurred with the introduction of selective serotonin subtype 3 (5-HT3) receptor antagonists, control of chemotherapy-induced nausea and vomiting (CINV) with first-generation agents (ondansetron, dolasetron, and granisetron) is less than ideal." | 8.82 | Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. ( Rubenstein, EB, 2004) |
| " The authors included all randomized controlled trials (RCTs) that had more than 25 patients per arm and compared ondansetron to granisetron for prophylaxis of acute (A) (< 24 hours) and delayed (D) (> 24 hours) nausea (N) and vomiting (V) induced by highly (H) or moderately (M) emetogenic chemotherapy." | 8.80 | Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. ( Caparroz, C; Castro, PC; del Giglio, A; Soares, HP, 2000) |
| " Ondansetron prevents emesis by blocking the 5-HT3 receptors associated with the vomiting reflex." | 8.78 | Experience with ondansetron in chemotherapy- and radiotherapy-induced emesis. ( Dicato, MA; Freeman, AJ, 1992) |
| "Nausea and vomiting have always been associated with anti-cancer agents in patients' minds because these effects were the main ones to occur during chemotherapy." | 7.78 | [Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting]. ( Depierre, A, 1996) |
| "The optimal dose of oral ondansetron for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) resulting from moderately emetogenic chemotherapy (MEC) is unknown." | 7.76 | The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit. ( Della-Fiorentina, SA; Ng, WL, 2010) |
| "Mirtazapine and olanzapine are easy-to-use psychiatric drugs with potent antinausea effects." | 7.74 | Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. ( Foley, KF; Kast, RE, 2007) |
| "The cost efficacy of various ondansetron regimens for the control of emesis induced by noncisplatin, moderately emetogenic chemotherapy was examined from a hospital perspective." | 7.71 | Cost-efficacy analysis of ondansetron regimens for control of emesis induced by noncisplatin, moderately emetogenic chemotherapy. ( Lachaine, J; Laurier, C, 2002) |
| "The control of emesis for patients undergoing high-dose chemotherapy with APBSCT is fair with ondansetron." | 7.70 | Use of ondansetron in the control of emesis in autologous peripheral blood stem cell transplant (APBSCT) for solid tumours. ( Ang, PT; Leong, SS; Tao, M; Teo, CP, 1998) |
| "Investigated the prevalence of anticipatory nausea and vomiting (ANV) among 59 pediatric cancer patients who had routinely received ondansetron (Zofran) antiemetic therapy and determined patient- and treatment-related factors associated with ANV." | 7.69 | Variables associated with anticipatory nausea and vomiting in pediatric cancer patients receiving ondansetron antiemetic therapy. ( Barclay, DR; Bieberich, AA; Mulhern, RK; Smith, BF; Tyc, VL, 1997) |
| "The aim of this study was to evaluate the efficacy and safety of ondansetron, an antagonist of 5-hydroxytryptamine type 3 (serotonin 3) (5-HT3) receptors, in controlling nausea and vomiting induced by antineoplastic therapy in children affected by cancer." | 7.68 | Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children. ( Calabria, C; Casale, F; Di Tullio, M; Indolfi, P; Lampa, E; Lucarelli, C; Matera, MG; Rossi, F, 1993) |
| "While ondansetron is effective in the control of nausea and vomiting induced by high dose cisplatin, it has to be given in multiple doses and is very expensive." | 7.68 | [Combined use of ondansetron and other anti-emetics to control cisplatin-induced nausea and vomiting]. ( Zeng, WY, 1993) |
| " Ondansetron, an antagonist of 5-hydroxytryptamine (subtype 3) receptor is a new, very potent drug preventing vomiting and nausea induced by different factors (chemotherapy, radiotherapy, anaesthesia)." | 7.68 | Ondansetron as an effective drug in prophylaxis of chemotherapy--induced emesis in children. ( Beshari, SE; Kołecki, P; Wachowiak, J, 1993) |
| "Patients on cancer chemotherapy, which has high occurrence of nausea and vomiting, were given either the low dose or the conventional dose of olanzapine for 3 days, in addition to some other antiemetic agents." | 7.01 | Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study. ( Banerjee, S; Bhattacharya, B; Biswas, S; Dutta, P; M Navari, R; Mukhopadhyay, S, 2021) |
| "Palonosetron (PG) is a newer, safe, and effective long-acting 5-HT3 antagonist commonly used in adults, but data in children are limited." | 6.90 | Palonosetron is a Better Choice Compared With Ondansetron for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in a Resource-limited Pediatric Oncology Center: Results From a Randomized Control Trial. ( Boddu, D; Chaudhary, NK; John, RR; Mahasampath, G; Mathew, LG; Nesadeepam, N, 2019) |
| "Rolapitant is a novel, long-acting neurokinin-1 (NK-1) receptor antagonist." | 6.80 | Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). ( Arora, S; Chua, D; Fein, LE; Poma, A; Rapoport, B; Wang, Y, 2015) |
| "Nausea and emesis are common side effects of opioid drugs administered for pain relief in cancer patients." | 6.70 | A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. ( Albertsson, M; Chimontsi-Kypriou, V; Curtis, P; Daly, S; Hardy, J; McQuade, B; Stathopoulos, P, 2002) |
| "Sixty cancer patients took part in this randomized prospective study." | 6.69 | Granisetron and ondansetron for chemotherapy-related nausea and vomiting. ( Ben Dayan, D; Ben Zion, T; Cohen, AM; Kaufman, O; Mittelman, M; Zeidman, A, 1998) |
| "A total of 427 cancer patients receiving cyclophosphamide chemotherapy participated in this multicenter, double-masked, double-dummy, parallel-group, randomized study comparing the antiemetic efficacy and safety of an 8-mg conventional ondansetron tablet (OT, n = 212) taken twice daily with an 8-mg orally disintegrating ondansetron tablet (ODT, n = 215) taken twice daily for 3 days." | 6.69 | Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: a multicenter, double-masked study. Ondansetron Orally Disintegrating Tablet Emesis Study Group. ( Curtis, P; Davidson, N; Erikstein, B; L'Esperance, B; Miller, I; Paska, W; Rapoport, B; Ruff, P, 1999) |
| "Ondansetron 24 mg q." | 6.69 | A multicenter, double-blind, randomized comparison of oral ondansetron 8 mg b.i.d., 24 mg q.d., and 32 mg q.d. in the prevention of nausea and vomiting associated with highly emetogenic chemotherapy. S3AA3012 Study Group. ( Ames, M; Brogden, J; Cohen, G; Craig, J; Diaz, LB; Garcia Rodriguez, FM; Krasnow, S; Miranda, E; Needles, B; Spector, J, 1999) |
| "Children who had solid tumors and who were receiving highly emetogenic chemotherapy, including cisplatin, carboplatin, cyclophosphamide, and ifosfamide, were randomized (1:1) in a double-blind fashion to receive either OND 0." | 6.68 | Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies. ( Alvarez, O; Bedros, A; Call, SK; Convy, L; Cook, L; Freeman, A; Halverson, J; Kalbermatter, O; Mick, K; Volsch, J, 1995) |
| "001) linear dose-response relationship was observed over the entire dolasetron dosage range for all efficacy parameters." | 6.68 | Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group. ( Chemaissani, A; Cognetti, F; Conte, PF; Cortes-Funes, H; Del Favero, A; Diaz-Rubio, E; Dressler, H; Duclos, B; Fauser, AA, 1996) |
| "Ondansetron is a 5-HT3 antagonist and its antiemetic properties have been established in adults receiving chemotherapy." | 6.67 | The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children. ( Hewitt, M; McQuade, B; Stevens, R, 1993) |
| "289 consecutive cancer patients receiving cisplatin chemotherapy (much greater than 50 mg/m2) were randomised to receive one of the following intravenous antiemetic regimens: ondansetron 0." | 6.67 | Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research. ( , 1992) |
| "Ondansetron 4 mg was administered orally once daily for 3-5 consecutive days." | 6.67 | [Investigation of anti-emetic effect of ondansetron tablet in multiple doses on nausea and emesis associated with cisplatin]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| " Several clinical observations suggested that ondansetron may be effective when given in a single dose: (1) demonstration of efficacy over a wide dose range, (2) similar efficacy with dosing intervals of 2, 4, 6, and 8 hours, and (3) efficacy of single-dose regimens with high-dose metoclopramide and other 5-hydroxytryptamine3 antagonists." | 6.67 | Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results. ( Hainsworth, JD; Hesketh, PJ, 1992) |
| "Ondansetron was administered as an 8 mg loading dose (A: 4 mg i." | 6.67 | The 5-HT3 receptor antagonist ondansetron re-establishes control in refractory emesis induced by non-cisplatin chemotherapy. ( de Mulder, PH; Lane-Allman, E; Seynaeve, C; van Liessum, PA; Verweij, J, 1991) |
| "Olanzapine significantly improved complete control of vomiting in the delayed phase." | 5.51 | Efficacy and Safety of Olanzapine in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double-blind Placebo-controlled Phase 3 Trial. ( Gupta, AK; Meena, JP; Moothedath, AW; Pandey, RM; Seth, R; Velpandian, T, 2022) |
| " The groups were analyzed and compared for frequency of vomiting, administered doses of on-demand antiemetic dimenhydrinate and adverse events during the acute (0-24 h after chemotherapy administration) and delayed (> 24 h-120 h) CINV phases." | 5.51 | Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study. ( Binder, V; Blaeschke, F; Cabanillas Stanchi, KM; Döring, M; Feucht, J; Feuchtinger, T; von Have, M; Willier, S, 2019) |
| "We assessed the efficacy of aprepitant (APR) or 10 or 5 mg OLN (OLN10 or OLN5) plus ondansetron and dexamethasone for chemotherapy-induced nausea/vomiting (CINV) prophylaxis in patients receiving high-emetogenic chemotherapy (HEC)." | 5.34 | Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy. ( Akewanlop, C; Danchaivijitr, P; Ithimakin, S; Korphaisarn, K; Laocharoenkiat, A; Nimmannit, A; Soparattanapaisarn, N; Techawattanawanna, S; Theeratrakul, P, 2020) |
| "The purpose of the study was to compare efficacy and toxicity of olanzapine (OLN; a higher-cost drug) and haloperidol (HAL; a lower-cost drug) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients who receive highly emetogenic chemotherapy (HEC)." | 5.30 | Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal. ( Acharya, B; Dulal, S; Neupane, P; Paudel, BD; Poudyal, BS; Shah, A; Shilpakar, R; Wood, LA, 2019) |
| "During late 1991, a series of severe adverse events involving thrombocytopenia, renal insufficiency and thrombotic episodes was observed in patients receiving emetogenic chemotherapy." | 5.28 | Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron. ( Childs, A; Coates, AS; Cox, K; Forsyth, C; Grygiel, JJ; Joshua, DE; McNeil, E, 1992) |
| "Palonosetron is non-inferior and cost-effective compared to ondansetron for prevention of acute chemotherapy-induced vomiting (CIV) in children receiving moderate and high emetogenic chemotherapy." | 5.27 | A randomized, open-label non-inferiority study to compare palonosetron and ondansetron for prevention of acute chemotherapy-induced vomiting in children with cancer receiving moderate or high emetogenic chemotherapy. ( Jain, S; Kapoor, G; Koneru, S; Vishwakarma, G, 2018) |
| " Complete response (CR; no vomiting and no rescue medication) rates in the acute, delayed, and overall phases (0-25, 25-120, and 0-120 h, respectively) were analyzed by chemotherapy type (carboplatin-based vs non-carboplatin-based), chemotherapy duration (single-day vs multiple-day), and baseline characteristics." | 5.27 | Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial. ( Beckford-Brathwaite, E; Camacho, E; Green, SA; Jordan, K; Khanani, S; Noga, SJ; Pong, A; Rapoport, BL; Weinstein, C, 2018) |
| "Subjects aged 6 months to 17 years scheduled to receive chemotherapeutic agents associated with at least moderate risk for emesis were randomly assigned to receive either aprepitant plus ondansetron (aprepitant regimen) or placebo plus ondansetron (control regimen); both could be administered with or without dexamethasone." | 5.27 | Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in paediatric subjects: An analysis by age group. ( DiCristina, C; Green, S; Kang, HJ; Loftus, S; Pong, A; Zwaan, CM, 2018) |
| "To investigate across multiple cycles the efficacy and safety of palonosetron in the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients receiving highly or moderately emetogenic chemotherapy (HEC/MEC)." | 5.24 | Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study. ( Basharova, E; Kabickova, E; Kovács, G; Nicolas, P; Spinelli, T; Wachtel, A, 2017) |
| "This study evaluated the efficacy and safety of a 3-day aprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting (CINV) during the first cycle of non-anthracycline plus cyclophosphamide (AC)-based moderately emetogenic chemotherapy (MEC) based on government guidelines in Korean patients." | 5.24 | Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. ( Ahn, MJ; Cho, CH; Cho, EK; Jang, JS; Jung, H; Kim, DJ; Kim, JE; Kim, JW; Lee, KY; Lee, MA; Lim, MC; Min, KW; Sung, YL; Sym, SJ, 2017) |
| "Palonosetron has shown efficacy in the prevention of chemotherapy-induced nausea and vomiting in adults undergoing moderately or highly emetogenic chemotherapy." | 5.22 | Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study. ( Basharova, EV; Kabickova, E; Kovács, G; Nicolas, P; Spinelli, T; Wachtel, AE, 2016) |
| "Significantly more patients receiving rolapitant than control reported no emesis or interfering nausea (combined measure) in cycles 2 (p = 0." | 5.22 | Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. ( Arora, S; Chasen, M; Navari, R; Powers, D; Rapoport, B; Schnadig, I; Schwartzberg, L, 2016) |
| "Aprepitant, a neurokinin-1 receptor antagonist, in combination with 5 HT-3 antagonist and dexamethasone is recommended in adults receiving moderately and highly emetogenic chemotherapy to reduce chemotherapy-induced vomiting (CIV)." | 5.20 | Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial. ( Bakhshi, S; Batra, A; Biswas, B; Dhawan, D; Paul, R; Sreenivas, V, 2015) |
| " It is showed that the use of 100 mg of ladasten, 16 mg of ondansetron orally per day and 50 mg of agomelatine per night is more effective in therapy for fatigue/weakness syndrome in incurable cancer patients compared to standard therapy." | 5.20 | [Optimization of pharmacological therapy for weakness syndrome in incurable patients]. ( Glushchenko, VA; Karitsky, AP; Kvashnin, AV; Rozengard, SA; Ryazankina, AA, 2015) |
| "To observe the therapeutic efficacy of Hewei Zhiou Recipe (HZR) combined ondansetron hydrochloride (OH) in treating vomiting in children patients with solid tumor." | 5.16 | [Treatment of vomiting in children patients with solid tumor by hewei zhiou recipe combined ondansetron hydrochloride]. ( Liu, ZM; Shi, X; Zhu, XD, 2012) |
| " Aprepitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting, is an inhibitor and inducer of CYP3A4." | 5.16 | Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies. ( Bannerji, R; Kantesaria, B; Mita, M; Poon, J; Shapiro, GI; Small, K; Statkevich, P; Tzontcheva, A; Zhang, D; Zhu, Y, 2012) |
| " For HEC, aprepitant reduced the risk of first emesis by 38-77% vs." | 5.15 | Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC). ( Carides, AD; Hesketh, PJ; Street, JC; Warr, DG, 2011) |
| "All doses of oral casopitant as a 3-day regimen (and likely as a 150-mg single oral dose) in combination with Ond/Dex provided significant improvement in the prevention of cisplatin-induced emesis." | 5.14 | Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting. ( Bandekar, RR; Dediu, M; Grunberg, SM; Ramlau, R; Roila, F; Rolski, J; Russo, MW, 2009) |
| "Aprepitant was shown previously to be effective for prevention of chemotherapy-induced nausea and vomiting (CINV) with moderately emetogenic chemotherapy (MEC) in breast cancer patients receiving an anthracycline and cyclophosphamide (AC)-based regimen." | 5.14 | Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. ( Boice, JA; Brown, C; Carides, A; Hardwick, JS; Jordan, K; Rapoport, BL; Schmoll, HJ; Taylor, A; Webb, T, 2010) |
| "The purpose of this phase III trial was to evaluate the efficacy and safety of regimens containing casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting during the first cycle in patients receiving moderately emetogenic chemotherapy (MEC)." | 5.14 | Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. ( Apornwirat, W; Aziz, Z; Grunberg, SM; Guckert, M; Herrstedt, J; Levin, J; Ranganathan, S; Roila, F; Russo, MW; Shaharyar, A; Van Belle, S, 2009) |
| "The addition of casopitant to ondansetron and dexamethasone in patients receiving HEC was significantly more effective in reducing the impact of nausea and vomiting on all daily life activities as assessed by the FLIE compared with ondansetron/dexamethasone dual therapy." | 5.14 | Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy. ( Blackburn, LM; Gridelli, C; Haiderali, AM; Lykopoulos, K; Russo, MW, 2010) |
| " This randomized, double-blind, double-dummy, multicenter study was designed to compare the efficacy and tolerance of metopimazine and ondansetron at preventing nausea and emesis in patients receiving chemotherapy." | 5.12 | A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis. ( Bensaoula, O; Bethune-Volters, A; Chidiac, J; Delgado, A; Di Palma, M; Khamales, S, 2006) |
| " Both drugs showed similar results in regard to chemotherapy-induced gastrointestinal side effects, emesis and appetite loss on day 1, but by day 5, ramosetron was significantly better than ondansetron in terms of controlling appetite loss." | 5.12 | Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study. ( Ai, B; Dong, M; Han, X; He, X; Huang, D; Liu, P; Shi, Y; Yang, S; Zhang, C; Zhou, S, 2007) |
| "To compare the efficacy and tolerability of dronabinol, ondansetron, or the combination for delayed chemotherapy-induced nausea and vomiting (CINV) in a 5-day, double-blind, placebo-controlled study." | 5.12 | Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. ( Baranowski, V; Barbato, LM; Carter, FJ; Jhangiani, H; Meiri, E; Vredenburgh, JJ; Yang, HM, 2007) |
| "In low dose cisplatin regimen, complete suppression of delayed emesis occurred in 55 per cent patients receiving ondansetron and in 30 per cent patients receiving metoclopramide." | 5.11 | Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis. ( Bhatia, A; Sharma, M; Tripathi, KD, 2004) |
| "The current analysis of > 1000 patients from 2 large randomized trials showed that in the subpopulation at increased risk of chemotherapy-induced nausea and vomiting due to concomitant emetogenic chemotherapy, the addition of aprepitant to standard antiemetics improved protection to an even greater extent than in the general study population." | 5.11 | Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomize ( Carides, AD; de Wit, R; Evans, JK; Gralla, RJ; Guoguang-Ma, J; Herrstedt, J; Horgan, KJ; Ianus, J, 2005) |
| "To compare the efficacy and tolerability of associations of metopimazine and ondansetron with methylprednisolone for the prevention of delayed chemotherapy-induced nausea and emesis." | 5.11 | Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy. ( Bloch, J; Delgado, A; Khayat, D; Meric, JB; Rixe, O, 2005) |
| "Although the L-758,298 and dexamethasone combination reduced acute (Day 1) emesis compared with historic rates, dual therapy with ondansetron and dexamethasone was superior in controlling acute emesis." | 5.10 | Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. ( Brestan, E; Bui, B; Carides, AD; De Smet, M; Decramer, ML; Eldridge, K; Evans, JK; Garin, AM; Gertz, BJ; Lichinitser, MR; Michiels, N; Navari, RM; Reinhardt, RR; Riviere, A; Thant, M; Van Belle, S, 2002) |
| "When it was added to a standard regimen of intravenous ondansetron and oral dexamethasone in the current study, aprepitant reduced chemotherapy-induced nausea and vomiting and was generally well tolerated, although increases in infection were noted that were assumed to be due to elevated dexamethasone levels as a result of the pharmacokinetic interaction." | 5.10 | Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. ( Carides, AD; Chawla, SP; Elmer, ME; Evans, JK; Gralla, RJ; Grunberg, SM; Hesketh, PJ; Horgan, KJ; Rittenberg, C; Schmidt, C; Taylor, A, 2003) |
| " In the present study, the Functional Living Index-Emesis (FLIE), was used to assess patient-reported impact of chemotherapy-induced nausea and vomiting (CINV) after administration of a new NK-1 receptor antagonist (aprepitant)." | 5.10 | Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. ( Cai, B; Carides, AD; Chawla, SP; Elmer, M; Grunberg, SM; Horgan, K; Martin, AR; Pearson, JD; Schmidt, C, 2003) |
| " The present study aimed to study the efficacy and tolerability of ondansetron versus (vs) metoclopramide in different dose related grades of cisplatin induced acute emesis." | 5.10 | Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy. ( Bhatia, A; Sharma, M; Tripathi, KD, 2003) |
| "Antiemetic treatment with tropisetron or ondansetron could be improved by adjustment for the CYP2D6 genotype; approximately 50 subjects would have to be genotyped to protect one patient from severe emesis." | 5.10 | Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. ( Bauer, S; Brockmöller, J; Kaiser, R; Papies, A; Possinger, K; Roots, I; Schelenz, C; Sezer, O; Tremblay, PB, 2002) |
| "A double-blind randomized comparison (protocol S3AB4003, Glaxo Wellcome, Great Britain) carried out in a group of 52 children showed that the 5-HT3-receptor antagonist ondansetron (in syrup) effectively prevented vomiting, nausea and loss of appetite caused in combination chemotherapy with highly- or moderately emetogenic cytostatic drugs in 92." | 5.09 | [Evaluation of the anti-emetic effectiveness of two drug formulations of Ondansetron in combined chemotherapy for children with malignant tumors]. ( Gershanovich, ML; Kolygin, BA; Punanov, IuA; Safonova, SA, 1999) |
| ") ondansetron with oral syrup ondansetron plus oral dexamethasone in the prevention of nausea and emesis in pediatric patients receiving moderately/highly emetogenic chemotherapy." | 5.09 | A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherap ( Breatnach, F; Daly, SA; Haigh, C; Hung, IJ; Kowalczyk, J; Leal, C; McKenna, CJ; Mitchell, T; Ninane, J; Smelhaus, V; White, L; Zhestkova, N, 2000) |
| "To compare ondansetron and domperidone for treatment of delayed nausea/vomiting (DN/V) following highly emetogenic chemotherapy, after attaining total suppression of emesis on the day of chemotherapy by mean of ondansetron (combined with dexamethasone in the case of cisplatin-treated patients)." | 5.08 | Prophylaxis of delayed nausea and vomiting after cancer chemotherapy. ( Borm, JJ; Esseboom, EU; Rojer, RA; Statius van Eps, LW, 1995) |
| "The antiemetic effect of ondansetron (Supplied by Qi Lu Pharmaceutical Company) in cisplatin-induced nausea and vomiting was studied in a randomized cross-over trial in 167 patients." | 5.08 | [The role of ondansetron (qi lu) in the prevention of cisplatin-induced vomiting--a randomized clinical trial]. ( Zeng, W; Zhang, P; Zhou, J, 1995) |
| "To compare the efficacy and safety of granisetron and ondansetron, serotonin (5-HT3) receptor antagonists shown to be effective in the prevention of chemotherapy-induced emesis." | 5.08 | Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. ( Fitts, D; Friedman, C; Gandara, D; Hall, S; Hesketh, P; Mailliard, J; Navari, R; Ritter, H, 1995) |
| "The aim of the study was to compare granisetron (GRA) with ondansetron (OND) in the prevention of acute emesis in consecutive chemotherapy-naive patients admitted to our department to receive a cytotoxic treatment containing cisplatinum (CP) at a dose > or = 50 mg/m2." | 5.08 | An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens. ( Angelelli, B; Guaraldi, M; Martoni, A; Pannuti, F; Strocchi, E, 1996) |
| "To assess the comparative antiemetic efficacy of single-dose intravenous (IV) dolasetron mesylate and ondansetron in preventing cisplatin-induced nausea and vomiting." | 5.08 | Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis P ( Anthony, L; Benedict, C; Gralla, R; Grote, T; Hahne, W; Hainsworth, J; Hesketh, P; Khojasteh, A; Kris, M; Navari, R; Tapazoglou, E, 1996) |
| "In contrast to the broad experience concerning the therapeutic use of carboplatin, only limited data are available regarding the patterns of carboplatin-induced emesis, one of its most distressing side effects." | 5.08 | Pattern of carboplatin-induced emesis. The German Ondansetron Study Group. ( Cramer-Giraud, U; du Bois, A; Fiola, M; Glaubitz, M; Thomssen, C; Vach, W, 1995) |
| "67% of patients given ondansetron had complete control of emesis compared with 45% of patients with placebo (P < 0." | 5.08 | A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy. ( Franzén, L; Hagberg, H; Henriksson, R; Jakobsson, M; Lomberg, H; Nyman, J; Nyth, AL; Sorbe, B, 1996) |
| "The purpose of this study was to investigate the efficacy and safety of oral ondansetron, given alone or in combination with dexamethasone in the control of cisplatin-induced delayed emesis." | 5.08 | A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. ( Depierre, A; Goedhals, L; McQuade, B; McRae, J; Olver, I; Paska, W; Seitz, JF; Stewart, DJ; Wilkinson, JR, 1996) |
| " Experimental investigations show that orally it is rapidly absorbed (about 90 min), is highly bioavailable (greater than 90%), has a long half-life (about 12 h) and is more potent (about 10 times) in animal models than ondansetron, currently standard therapy for the prophylactic control of chemotherapy induced nausea and vomiting." | 5.08 | Comparison of oral itasetron with oral ondansetron: results of a double-blind, active-controlled phase II study in chemotherapy-naive patients receiving moderately emetogenic chemotherapy. ( Egerer, G; Goldschmidt, H; Kempe, R; Salwender, H; Voigt, T, 1997) |
| "The efficacy and safety of ondansetron 8 mg BID compared with 8 mg TID for 3 days in the prevention of nausea and vomiting in 402 patients on cyclophosphamide (> or = 500 mg/m2)-based chemotherapy were evaluated in a multicenter, randomized, double-blind, stratified study." | 5.08 | Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group. ( Beck, TM; Chang, A; Griffin, D; Harvey, WH; Meshad, M; Navari, R; Wentz, A; York, M, 1997) |
| " Combination of corticosteroids with ondansetron enables greater control of emesis than that obtained with ondansetron alone, but some patients still experience symptoms." | 5.08 | The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French Ondansetron Study Group. ( d'Allens, H; Depierre, A; Giovannini, M; Hédouin, M; Kaluzinski, L; Lebeau, B; Rivière, A; Votan, B, 1997) |
| "The purpose of our study was to evaluate the effectiveness of alprazolam (APZ) as an adjuvant drug to ondansentron against cisplatin-induced emesis." | 5.07 | Comparison of ondansentron (GR 38032F) versus ondansentron plus alprazolam as antiemetic prophylaxis during cisplatin-containing chemotherapy. ( Bacoyiannis, C; Charalambidis, G; Karabelis, A; Kosmidis, P; Mylonakis, N; Pagou, M; Tsavaris, N, 1994) |
| "The antiemetic efficacy of ondansetron and dexamethasone (Ondex) was randomly compared to that of high-dose metoclopramide, dexamethasone, and orphenadrine (Control) in the prevention of emesis induced by cyclophosphamide-doxorubicin chemotherapy in 64 chemotherapy-naive breast cancer patients." | 5.07 | Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses ( Campora, E; Giudici, S; Merlini, L; Rosso, R; Rubagotti, A, 1994) |
| "This study compares the efficacy and safety of ondansetron alone with that of ondansetron plus dexamethasone in the prevention of emesis induced by high-dose cisplatin (> or = 100 mg/m2)." | 5.07 | A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. ( Beck, TM; Bricker, LJ; Hainsworth, JD; Haley, B; Harker, WG; Harvey, WH; Hesketh, PJ; Kish, JA; Murphy, WK; Ryan, T, 1994) |
| "Ondansetron, a selective 5-HT3 antagonist, has been shown to be effective in preventing chemotherapy-induced nausea and vomiting." | 5.07 | Use of oral and intravenous ondansetron in patients treated with cisplatin. ( Ang, PT; Au, E; Khoo, KS; Soh, LT, 1993) |
| "One-hundred and forty-five chemotherapy patients receiving cisplatin- and non-cisplatin-containing regimens participated in an open evaluation of ondansetron, a 5-HT3 receptor antagonist, in the prophylaxis of acute and delayed nausea and vomiting." | 5.07 | Ondansetron in the treatment of nausea and vomiting induced by chemotherapy. Portuguese Ondansetron Study Group. ( Batarda, M; Brandão, A; de Faria, L; de Matos, E; dos Reis, F; Fráguas, A; Ribeiro, I; Ribeiro, M; Ribiero, MM; Uva, S, 1993) |
| "We evaluated the efficacy and safety of oral ondansetron, a selective antagonist of 5-HT3 receptors, for the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapy (> 500 mg/m2)." | 5.07 | Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group. ( Burton, G; Ciociola, AA; Cubeddu, LX; Galvin, D; Meshad, M; Pendergrass, K; Ryan, T; York, M, 1994) |
| "To compare the effectiveness and side effects of antiemetic regimens using ondansetron alone (O) versus ondansetron plus dexamethasone (OD) versus ondansetron plus dexamethasone plus lorazepam (ODA) in the prevention of emesis induced by cisplatin-based chemotherapy." | 5.07 | A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy. ( Ahn, MJ; Choi, SS; Kim, SH; Lee, JS; Lee, KH; Suh, C, 1994) |
| "One hundred cancer patients receiving non-cisplatin containing chemotherapy were entered in a prospective study in which the efficacy of ondansetron was compared with standard antiemetic treatments in the prophylaxis of nausea and emesis." | 5.07 | Comparison of ondansetron with customary treatment in the prophylaxis of nausea and emesis induced by non-cisplatin containing chemotherapy. ( Flander, MK; Heikkinen, MI; Jantunen, IT; Kataja, VV; Kuoppala, TA; Teerenhovi, L, 1993) |
| "166 patients receiving moderately emetogenic chemotherapy were entered into a randomised prospective study in which the efficacy of single dose ondansetron 8 mg, tropisetron 5 mg and granisetron 3 mg in the prophylaxis of acute vomiting was evaluated." | 5.07 | 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy--a randomised study. ( Flander, MK; Jantunen, IT; Kataja, VV; Muhonen, TT; Teerenhovi, L, 1993) |
| "A total of 535 chemotherapy naive, hospitalised patients (263 male/272 female) scheduled to receive cisplatin (50-120 mg m-2)-containing regimens participated in a randomised, double-blind, parallel group study to evaluate the efficacy and safety of three intravenous dose schedules of ondansetron in the prophylaxis of acute nausea and emesis." | 5.07 | Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Stu ( Buser, K; Christmann, D; Kitchener, H; Paes, D; Porteder, H; Schmidt, M; Schuller, J; Sevelda, P; Seynaeve, C; Van Belle, S, 1992) |
| "The anti-emetic effect, safety and clinical usefulness of ondansetron for the treatment of nausea and vomiting caused by anticancer drugs including cisplatin, was evaluated by a multi-institutional study in patients with various malignancies." | 5.07 | [Evaluation of SN-307 (ondansetron), given intravenously for the treatment of nausea and vomiting caused by anticancer drugs including cisplatin-open study]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Clinical usefulness of ondansetron as an antiemetic for the treatment of nausea and vomiting induced by anticancer drugs including cisplatin (> or = 50 mg/m2) was evaluated by a multi-institutional, double-blind comparative study with placebo with inpatients with various malignancies." | 5.07 | [Evaluation of SN-307 (ondansetron), given intravenously in the treatment of nausea and vomiting caused by anticancer drugs including cisplatin--a placebo-controlled, double-blind comparative study]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| " Costs, effects and cost-effectiveness of ondansetron in the prophylaxis of acute nausea and vomiting induced by chemotherapy are assessed relative to antiemetic therapy with metoclopramide." | 5.07 | Economic evaluation of ondansetron: preliminary analysis using clinical trial data prior to price setting. ( Buxton, MJ; O'Brien, BJ, 1992) |
| "The selective 5-hydroxytryptamine3 antagonist ondansetron has been shown to be effective in preventing nausea and vomiting associated with highly emetogenic cisplatin chemotherapy." | 5.07 | Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials. ( Beck, TM, 1992) |
| "In an open, drug-oriented phase-II/III-study 24 patients were treated with the 5-HT3-antagonist Ondansetron as an antiemetic drug for chemotherapy-induced nausea and emesis." | 5.06 | [Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study]. ( Berdel, WE; Ertl, A; Fink, U; Perker, M; Reichold, M; Serve, H, 1990) |
| " Ondansetron exhibited similar efficacy than granisetron and tropisetron, as well as greater efficacy than dolasetron for acute vomiting." | 4.93 | Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis. ( Acúrcio, Fde A; Andrade, EI; Cherchiglia, ML; De Araújo, VE; Marra, LP; Reis, IA; Simino, GP, 2016) |
| "Despite the advance in supportive care that occurred with the introduction of selective serotonin subtype 3 (5-HT3) receptor antagonists, control of chemotherapy-induced nausea and vomiting (CINV) with first-generation agents (ondansetron, dolasetron, and granisetron) is less than ideal." | 4.82 | Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. ( Rubenstein, EB, 2004) |
| " The authors included all randomized controlled trials (RCTs) that had more than 25 patients per arm and compared ondansetron to granisetron for prophylaxis of acute (A) (< 24 hours) and delayed (D) (> 24 hours) nausea (N) and vomiting (V) induced by highly (H) or moderately (M) emetogenic chemotherapy." | 4.80 | Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. ( Caparroz, C; Castro, PC; del Giglio, A; Soares, HP, 2000) |
| "Ondansetron is more effective than high-dose metoclopramide in the prevention of acute nausea and vomiting due to highly emetogenic chemotherapy, and, unlike metoclopramide, is rarely associated with extrapyramidal effects." | 4.78 | Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy. ( Milne, RJ; Plosker, GL, 1992) |
| " Ondansetron, currently the only serotonin antagonist with Food and Drug Administration approval for treatment of chemotherapy-induced emesis, demonstrates the efficacy and potential advantages of this class of antiemetics." | 4.78 | Emesis as a complication of cancer chemotherapy: pathophysiology, importance, and treatment. ( Graves, T, 1992) |
| " Ondansetron prevents emesis by blocking the 5-HT3 receptors associated with the vomiting reflex." | 4.78 | Experience with ondansetron in chemotherapy- and radiotherapy-induced emesis. ( Dicato, MA; Freeman, AJ, 1992) |
| "Nausea and vomiting have always been associated with anti-cancer agents in patients' minds because these effects were the main ones to occur during chemotherapy." | 3.78 | [Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting]. ( Depierre, A, 1996) |
| " Ondansetron 8 mg and dexamethasone 8 mg intravenously were the standard antiemetic therapy for prevention of acute chemotherapy-induced nausea and vomiting." | 3.77 | Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. ( Baak-Pablo, RF; Gelderblom, H; Guchelaar, HJ; Hakimi, M; Mustofa, M; Nortier, JW; Perwitasari, DA; van der Straaten, RJ; Wessels, JA, 2011) |
| "The optimal dose of oral ondansetron for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) resulting from moderately emetogenic chemotherapy (MEC) is unknown." | 3.76 | The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit. ( Della-Fiorentina, SA; Ng, WL, 2010) |
| "Mirtazapine and olanzapine are easy-to-use psychiatric drugs with potent antinausea effects." | 3.74 | Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. ( Foley, KF; Kast, RE, 2007) |
| " Dolasetron ( n=157), granisetron ( n=81), and ondansetron ( n=131) achieved complete control of vomiting in 89." | 3.74 | Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist? ( Awan, FT; Chaudhary, L; Hamadani, M; Khan, JK; Kojouri, K; Ozer, H; Tfayli, A, 2007) |
| "In highly emetogenic chemotherapy, the recommended dose of the serotonin-receptor antagonist ondansetron (5 mg/m(2) q8h) may be insufficient to prevent chemotherapy-induced nausea and vomiting." | 3.74 | Safety of ondansetron loading doses in children with cancer. ( Ammann, RA; Hasler, SB; Hirt, A; Leibundgut, KK; Ridolfi Luethy, A, 2008) |
| "The cost efficacy of various ondansetron regimens for the control of emesis induced by noncisplatin, moderately emetogenic chemotherapy was examined from a hospital perspective." | 3.71 | Cost-efficacy analysis of ondansetron regimens for control of emesis induced by noncisplatin, moderately emetogenic chemotherapy. ( Lachaine, J; Laurier, C, 2002) |
| "The control of emesis for patients undergoing high-dose chemotherapy with APBSCT is fair with ondansetron." | 3.70 | Use of ondansetron in the control of emesis in autologous peripheral blood stem cell transplant (APBSCT) for solid tumours. ( Ang, PT; Leong, SS; Tao, M; Teo, CP, 1998) |
| "Investigated the prevalence of anticipatory nausea and vomiting (ANV) among 59 pediatric cancer patients who had routinely received ondansetron (Zofran) antiemetic therapy and determined patient- and treatment-related factors associated with ANV." | 3.69 | Variables associated with anticipatory nausea and vomiting in pediatric cancer patients receiving ondansetron antiemetic therapy. ( Barclay, DR; Bieberich, AA; Mulhern, RK; Smith, BF; Tyc, VL, 1997) |
| "The aim of this study was to evaluate the efficacy and safety of ondansetron, an antagonist of 5-hydroxytryptamine type 3 (serotonin 3) (5-HT3) receptors, in controlling nausea and vomiting induced by antineoplastic therapy in children affected by cancer." | 3.68 | Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children. ( Calabria, C; Casale, F; Di Tullio, M; Indolfi, P; Lampa, E; Lucarelli, C; Matera, MG; Rossi, F, 1993) |
| "While ondansetron is effective in the control of nausea and vomiting induced by high dose cisplatin, it has to be given in multiple doses and is very expensive." | 3.68 | [Combined use of ondansetron and other anti-emetics to control cisplatin-induced nausea and vomiting]. ( Zeng, WY, 1993) |
| " Ondansetron, an antagonist of 5-hydroxytryptamine (subtype 3) receptor is a new, very potent drug preventing vomiting and nausea induced by different factors (chemotherapy, radiotherapy, anaesthesia)." | 3.68 | Ondansetron as an effective drug in prophylaxis of chemotherapy--induced emesis in children. ( Beshari, SE; Kołecki, P; Wachowiak, J, 1993) |
| "Patients on cancer chemotherapy, which has high occurrence of nausea and vomiting, were given either the low dose or the conventional dose of olanzapine for 3 days, in addition to some other antiemetic agents." | 3.01 | Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study. ( Banerjee, S; Bhattacharya, B; Biswas, S; Dutta, P; M Navari, R; Mukhopadhyay, S, 2021) |
| "Palonosetron (PG) is a newer, safe, and effective long-acting 5-HT3 antagonist commonly used in adults, but data in children are limited." | 2.90 | Palonosetron is a Better Choice Compared With Ondansetron for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in a Resource-limited Pediatric Oncology Center: Results From a Randomized Control Trial. ( Boddu, D; Chaudhary, NK; John, RR; Mahasampath, G; Mathew, LG; Nesadeepam, N, 2019) |
| "Rolapitant is a novel, long-acting neurokinin-1 (NK-1) receptor antagonist." | 2.80 | Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). ( Arora, S; Chua, D; Fein, LE; Poma, A; Rapoport, B; Wang, Y, 2015) |
| " These results should allow a better individualization of etoposide dosing in children." | 2.76 | Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect. ( Auvrignon, A; Chastagner, P; Corradini, N; Doz, F; Gentet, JC; Giraud, C; Leblond, P; Rey, E; Rubie, H; Treluyer, JM; Urien, S; Vassal, G, 2011) |
| "Fourteen cancer patients were enrolled in this phase 1, open-label, randomized, two-period crossover study." | 2.76 | Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer. ( Adams, LM; Bauman, J; Dandamudi, UB; Gartner, E; Hohl, R; Johnson, B; Lewis, LD; Morris, S; Murray, S; Webb, RT, 2011) |
| "Nausea and vomiting are important symptoms observed in cancer patients." | 2.74 | Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial. ( de Camargo, B; del Giglio, A; Lajolo, PP, 2009) |
| "Eighty-five in-patients with cancer undergoing chemotherapy were randomly divided into 2 groups: Nasea group (group A, n = 43, Nasea, ramosetron hydrochloride was injected intravenously 30 minutes before chemotherapy) and ondansetron group (group B, n = 42, ondamsetron was injected intravenously 30 minutes before chemotherapy)." | 2.71 | [Effects of Nasea on prevention of gastrointestinal side effects caused by chemotherapeutic drugs]. ( Liu, DW; Liu, YY; Shan, XJ; Xie, XD; Zheng, ZD, 2003) |
| "Patients with cancer (N = 216) treated with chemotherapeutic regimens composed of highly or moderately emetogenic agents were examined for their antiemetic responses to tropisetron, ondansetron, or granisetron." | 2.71 | Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. ( Abali, H; Aynacioglu, AS; Babaoglu, MO; Bayar, B; Bozkurt, A; Celik, I; Kerb, R, 2005) |
| "Nausea and emesis are common side effects of opioid drugs administered for pain relief in cancer patients." | 2.70 | A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. ( Albertsson, M; Chimontsi-Kypriou, V; Curtis, P; Daly, S; Hardy, J; McQuade, B; Stathopoulos, P, 2002) |
| "Sixty cancer patients took part in this randomized prospective study." | 2.69 | Granisetron and ondansetron for chemotherapy-related nausea and vomiting. ( Ben Dayan, D; Ben Zion, T; Cohen, AM; Kaufman, O; Mittelman, M; Zeidman, A, 1998) |
| "A total of 427 cancer patients receiving cyclophosphamide chemotherapy participated in this multicenter, double-masked, double-dummy, parallel-group, randomized study comparing the antiemetic efficacy and safety of an 8-mg conventional ondansetron tablet (OT, n = 212) taken twice daily with an 8-mg orally disintegrating ondansetron tablet (ODT, n = 215) taken twice daily for 3 days." | 2.69 | Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: a multicenter, double-masked study. Ondansetron Orally Disintegrating Tablet Emesis Study Group. ( Curtis, P; Davidson, N; Erikstein, B; L'Esperance, B; Miller, I; Paska, W; Rapoport, B; Ruff, P, 1999) |
| "Patients with metastatic cancer who were not undergoing chemotherapy or radiotherapy and who had lost >5% of their body weight were eligible." | 2.69 | Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome. ( Edelman, MJ; Gandara, DR; Gietzen, DW; Houston, J; Ishii, R; Lauder, I; Meyers, FJ; O'Mahony, M; Uhrich, M, 1999) |
| "Ondansetron 24 mg q." | 2.69 | A multicenter, double-blind, randomized comparison of oral ondansetron 8 mg b.i.d., 24 mg q.d., and 32 mg q.d. in the prevention of nausea and vomiting associated with highly emetogenic chemotherapy. S3AA3012 Study Group. ( Ames, M; Brogden, J; Cohen, G; Craig, J; Diaz, LB; Garcia Rodriguez, FM; Krasnow, S; Miranda, E; Needles, B; Spector, J, 1999) |
| "In patients with cancer (n = 16), baseline blood dialysate 5-HIAA concentrations averaged 2." | 2.69 | Use of intravenous microdialysis to monitor changes in serotonin release and metabolism induced by cisplatin in cancer patients: comparative effects of granisetron and ondansetron. ( Castejon, AM; Cubeddu, LX; Hernandez, L; Paez, X, 1999) |
| " Serial plasma and pleural or ascitic fluid samples were collected during each dosing and analyzed by high-performance liquid chromatography for both the intact lactone form of topotecan and its ring-opened carboxylate form." | 2.69 | Topotecan lacks third space sequestration. ( de Jonge, MJ; Gelderblom, H; Loos, WJ; Sparreboom, A; Verweij, J, 2000) |
| "Metoclopramide was given i." | 2.68 | Ondansetron versus metoclopramide as antiemetic treatment during cisplatin-based chemotherapy. A prospective study with special regard to regard to electrolyte imbalance. ( Benou, N; Charalambidis, G; Ganas, N; Karabellis, A; Kosmidis, P; Mylonakis, N; Pagou, M; Tsavaris, N; Tsikalakis, D, 1995) |
| "Children who had solid tumors and who were receiving highly emetogenic chemotherapy, including cisplatin, carboplatin, cyclophosphamide, and ifosfamide, were randomized (1:1) in a double-blind fashion to receive either OND 0." | 2.68 | Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies. ( Alvarez, O; Bedros, A; Call, SK; Convy, L; Cook, L; Freeman, A; Halverson, J; Kalbermatter, O; Mick, K; Volsch, J, 1995) |
| "Nausea was absent or mild in 79% of patients on day 1, 45% on day 2 and 41% on day 3." | 2.68 | A phase II study of ondansetron as antiemetic prophylaxis in patients receiving high-dose polychemotherapy and stem cell transplantation. ( Barbounis, V; Efremidis, AP; Hatzichristou, H; Koumakis, G; Tsousis, S; Vassilomanolakis, M, 1995) |
| "001) linear dose-response relationship was observed over the entire dolasetron dosage range for all efficacy parameters." | 2.68 | Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group. ( Chemaissani, A; Cognetti, F; Conte, PF; Cortes-Funes, H; Del Favero, A; Diaz-Rubio, E; Dressler, H; Duclos, B; Fauser, AA, 1996) |
| "Paclitaxel dosage was escalated in 10 mg/m2/wk increments in subsequent patients, to a maximum dosage of 90 mg/m2/wk." | 2.68 | Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial. ( Freund, W; Hausamen, TU; Lipke, J; Löffler, TM, 1996) |
| " Absolute bioavailability after the oral dosing on day 1 was 87." | 2.67 | Oral ondansetron pharmacokinetics: the effect of chemotherapy. ( Bjurstrom, T; Bozigian, HP; Gooding, AE; Griffin, RH; Hansen, LA; Hsyu, PH; Huang, AT; Mitchell, R; Panella, TL; Pritchard, JF, 1994) |
| "Ondansetron was a very effective antiemetic in the first weeks of treatment but its efficacy waned later on." | 2.67 | Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours. ( de Boer-Dennert, M; Planting, AS; Stoter, G; van der Burg, ME; Verweij, J, 1993) |
| "Ondansetron is a 5-HT3 antagonist and its antiemetic properties have been established in adults receiving chemotherapy." | 2.67 | The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children. ( Hewitt, M; McQuade, B; Stevens, R, 1993) |
| "289 consecutive cancer patients receiving cisplatin chemotherapy (much greater than 50 mg/m2) were randomised to receive one of the following intravenous antiemetic regimens: ondansetron 0." | 2.67 | Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research. ( , 1992) |
| "Ondansetron 4 mg was administered orally once daily for 3-5 consecutive days." | 2.67 | [Investigation of anti-emetic effect of ondansetron tablet in multiple doses on nausea and emesis associated with cisplatin]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Ondansetron was given as anti-emetic prophylaxis to 429 children receiving a variety of emetogenic cancer treatments for up to 8 days, in three, open, multicentre, European studies." | 2.67 | Ondansetron as prophylaxis for chemotherapy and radiotherapy-induced emesis in children. ( Jürgens, H; McQuade, B, 1992) |
| " Several clinical observations suggested that ondansetron may be effective when given in a single dose: (1) demonstration of efficacy over a wide dose range, (2) similar efficacy with dosing intervals of 2, 4, 6, and 8 hours, and (3) efficacy of single-dose regimens with high-dose metoclopramide and other 5-hydroxytryptamine3 antagonists." | 2.67 | Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results. ( Hainsworth, JD; Hesketh, PJ, 1992) |
| "Ondansetron was administered as an 8 mg loading dose (A: 4 mg i." | 2.67 | The 5-HT3 receptor antagonist ondansetron re-establishes control in refractory emesis induced by non-cisplatin chemotherapy. ( de Mulder, PH; Lane-Allman, E; Seynaeve, C; van Liessum, PA; Verweij, J, 1991) |
| "Bone cancer was the most incident (≥50%) neoplasm, followed by rhabdomyosarcoma and Hodgkin's lymphoma." | 2.55 | Aprepitant in pediatric patients using moderate and highly emetogenic protocols: a systematic review and meta-analyses of randomized controlled trials. ( D'Athayde Rodrigues, F; Ferreira, MAP; Moreira, LB; Okumura, LM, 2017) |
| "The purpose of this article is to outline the risk of cardiac adverse events (AEs) from 5-HT3-RAs, with focus on the three most commonly used, ondansetron, granisetron and palonosetron." | 2.50 | 5-Hydroxytryptamine3 receptor antagonists and cardiac side effects. ( Brygger, L; Herrstedt, J, 2014) |
| "Emesis is not only unpleasant, but negatively impacts on global quality of life." | 2.43 | Update on anti-emetics for chemotherapy-induced emesis. ( Olver, IN, 2005) |
| "Ondansetron was found to be safe and effective in the control of acute and delayed emesis in all treatment groups." | 2.38 | [Use of ondansetron, a 5-HT3 receptor antagonist, as a new type of antiemetic in pediatric oncology]. ( Borsi, J; Csáki, C; Ferencz, T; Koós, R; Schuler, D, 1993) |
| "Ondansetron failure was determined by review of the medical records and by patient-reported outcomes (PROs)." | 1.72 | Pharmacogenetic and clinical predictors of ondansetron failure in a diverse pediatric oncology population. ( Davenport, L; Dome, JS; Gai, J; Gross, AM; Hinds, PS; Jacobs, SS; Mowbray, C; Postell, E; van den Anker, JN, 2022) |
| " The groups were analyzed and compared for frequency of vomiting, administered doses of on-demand antiemetic dimenhydrinate and adverse events during the acute (0-24 h after chemotherapy administration) and delayed (> 24 h-120 h) CINV phases." | 1.51 | Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study. ( Binder, V; Blaeschke, F; Cabanillas Stanchi, KM; Döring, M; Feucht, J; Feuchtinger, T; von Have, M; Willier, S, 2019) |
| " Blood samples for vinorelbine pharmacokinetic analysis were collected over 96 h." | 1.34 | Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. ( de Bruijn, P; de Wit, R; Freedman, SJ; Gambale, JJ; Li, S; Loos, WJ; Murphy, GM; Van Dyck, K; van Noort, C; Verweij, J, 2007) |
| "We included 242 cancer patients on their first day of chemotherapy." | 1.32 | Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. ( Brockmoller, J; Kaiser, R; Possinger, K; Roots, I; Rosler, N; Schelenz, C; Sezer, O; Tremblay, PB, 2003) |
| "Treatment with ondansetron was well tolerated, onset of action was rapid, and response rates were high and sustained over time." | 1.30 | Use of ondansetron in palliative medicine. ( Cooney, NJ; Coughlan, M; Currow, DC; Fardell, B, 1997) |
| "Fluoxetine (Prozac) is an effective and increasingly widely used antidepressant." | 1.29 | Fluoxetine treatment comprises the antiemetic efficacy of ondansetron in cancer patients. ( Koriech, OM, 1995) |
| "The treatment of cancer patients has improved over the few past years." | 1.29 | [Future trends in chemotherapy and impact on the management of emesis]. ( Catimel, G; Droz, JP, 1995) |
| " Thus, controlling the adverse side effects associated with radiation therapy is critical to optimal patient care." | 1.29 | Controlling the toxicity of palliative radiotherapy: the role of 5-HT3 antagonists. ( Priestman, TJ, 1996) |
| "During late 1991, a series of severe adverse events involving thrombocytopenia, renal insufficiency and thrombotic episodes was observed in patients receiving emetogenic chemotherapy." | 1.28 | Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron. ( Childs, A; Coates, AS; Cox, K; Forsyth, C; Grygiel, JJ; Joshua, DE; McNeil, E, 1992) |
| "A total of 28 patients receiving cancer chemotherapy with cisplatin-containing regimens (70-120 mg/m2) participated in an evaluation of the efficacy and safety of GR38032F for the prevention of acute nausea and vomiting." | 1.28 | GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting. ( Bons, J; Brion, N; Droz, JP; Marty, M; Paule, B; Pouillart, P, 1989) |
| "Ondansetron was found to have a very good safety profile, and the only toxicity identified was associated with central nervous system activity when near lethal doses were administered." | 1.28 | Ondansetron: pre-clinical safety evaluation. ( Capel-Edwards, K; Jackson, MR; Scales, MD; Spurling, NW; Tucker, ML; Tweats, DJ, 1989) |
| " Ten dosage levels were explored, ranging from 0." | 1.27 | Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy. ( Clark, RA; Gralla, RJ; Kris, MG; Tyson, LB, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (2.07) | 18.7374 |
| 1990's | 94 (48.70) | 18.2507 |
| 2000's | 54 (27.98) | 29.6817 |
| 2010's | 34 (17.62) | 24.3611 |
| 2020's | 7 (3.63) | 2.80 |
| Authors | Studies |
|---|---|
| Jacobs, SS | 1 |
| Dome, JS | 1 |
| Gai, J | 1 |
| Gross, AM | 1 |
| Postell, E | 1 |
| Hinds, PS | 1 |
| Davenport, L | 1 |
| van den Anker, JN | 1 |
| Mowbray, C | 1 |
| Moothedath, AW | 1 |
| Meena, JP | 1 |
| Gupta, AK | 1 |
| Velpandian, T | 1 |
| Pandey, RM | 1 |
| Seth, R | 1 |
| França de Moraes, GH | 1 |
| Lima, LC | 1 |
| Couceiro, TCM | 1 |
| Lins, MM | 1 |
| Cumino, DO | 1 |
| Simões, LABM | 1 |
| Mello, MJG | 1 |
| Navari, RM | 2 |
| Willier, S | 1 |
| Cabanillas Stanchi, KM | 1 |
| von Have, M | 1 |
| Binder, V | 1 |
| Blaeschke, F | 1 |
| Feucht, J | 1 |
| Feuchtinger, T | 1 |
| Döring, M | 1 |
| Ithimakin, S | 1 |
| Theeratrakul, P | 1 |
| Laocharoenkiat, A | 1 |
| Nimmannit, A | 1 |
| Akewanlop, C | 1 |
| Soparattanapaisarn, N | 1 |
| Techawattanawanna, S | 1 |
| Korphaisarn, K | 1 |
| Danchaivijitr, P | 1 |
| Kamath, A | 1 |
| Rai, KM | 1 |
| Shreyas, R | 1 |
| Saxena, PUP | 1 |
| Banerjee, S | 2 |
| Mukhopadhyay, S | 1 |
| Dutta, P | 1 |
| Bhattacharya, B | 1 |
| Biswas, S | 1 |
| M Navari, R | 1 |
| Kovács, G | 2 |
| Wachtel, A | 1 |
| Basharova, E | 1 |
| Spinelli, T | 2 |
| Nicolas, P | 2 |
| Kabickova, E | 2 |
| Tan, J | 1 |
| Wang, S | 1 |
| Liang, X | 1 |
| Li, CC | 1 |
| Zhang, J | 1 |
| Zhao, Z | 1 |
| Kong, XR | 1 |
| Deng, X | 1 |
| Peng, L | 1 |
| Yang, C | 1 |
| Jain, S | 1 |
| Kapoor, G | 1 |
| Koneru, S | 1 |
| Vishwakarma, G | 1 |
| Weinstein, C | 1 |
| Jordan, K | 3 |
| Green, SA | 1 |
| Camacho, E | 1 |
| Khanani, S | 1 |
| Beckford-Brathwaite, E | 1 |
| Pong, A | 2 |
| Noga, SJ | 1 |
| Rapoport, BL | 2 |
| Kang, HJ | 1 |
| Loftus, S | 1 |
| DiCristina, C | 1 |
| Green, S | 1 |
| Zwaan, CM | 1 |
| Osman, AAM | 1 |
| Elhassan, MMA | 1 |
| AbdElrahim, BHA | 1 |
| Ahmed, FHA | 1 |
| Yousif, JBH | 1 |
| Ahmed, MAM | 1 |
| Abdelhafeez, RHA | 1 |
| Ahmed, UMY | 1 |
| Dulal, S | 1 |
| Paudel, BD | 1 |
| Neupane, P | 1 |
| Shah, A | 1 |
| Acharya, B | 1 |
| Poudyal, BS | 1 |
| Shilpakar, R | 1 |
| Wood, LA | 1 |
| Chaudhary, NK | 1 |
| John, RR | 1 |
| Boddu, D | 1 |
| Mahasampath, G | 1 |
| Nesadeepam, N | 1 |
| Mathew, LG | 1 |
| McKenzie, E | 1 |
| Chan, D | 1 |
| Parsafar, S | 1 |
| Razvi, Y | 1 |
| McFarlane, T | 1 |
| Rico, V | 1 |
| Pasetka, M | 1 |
| DeAngelis, C | 1 |
| Chow, E | 1 |
| Nichols, D | 1 |
| Arnold, S | 1 |
| Weiss, HL | 1 |
| Wu, J | 1 |
| Durbin, EB | 1 |
| Miller, R | 1 |
| Kolesar, J | 1 |
| Schwartzberg, L | 2 |
| Barbour, SY | 1 |
| Morrow, GR | 2 |
| Ballinari, G | 1 |
| Thorn, MD | 1 |
| Cox, D | 1 |
| Bodge, M | 1 |
| Shillingburg, A | 1 |
| Paul, S | 1 |
| Biondo, L | 1 |
| Brygger, L | 1 |
| Herrstedt, J | 5 |
| Bakhshi, S | 1 |
| Batra, A | 1 |
| Biswas, B | 1 |
| Dhawan, D | 1 |
| Paul, R | 1 |
| Sreenivas, V | 1 |
| Motamed, C | 1 |
| Bourgain, JL | 1 |
| Rapoport, B | 3 |
| Chua, D | 1 |
| Poma, A | 1 |
| Arora, S | 2 |
| Wang, Y | 1 |
| Fein, LE | 1 |
| Ryazankina, AA | 1 |
| Rozengard, SA | 1 |
| Glushchenko, VA | 1 |
| Karitsky, AP | 1 |
| Kvashnin, AV | 1 |
| Kim, HJ | 2 |
| Shin, SW | 1 |
| Song, EK | 1 |
| Lee, NR | 1 |
| Kim, JS | 1 |
| Ahn, JS | 1 |
| Yun, HJ | 1 |
| Cho, YH | 1 |
| Park, KU | 1 |
| Kim, SY | 1 |
| Jang, JS | 2 |
| Kim, SW | 1 |
| Lee, HW | 1 |
| Lee, SR | 1 |
| Kim, YS | 1 |
| Lee, SN | 1 |
| Ko, YH | 1 |
| Kang, JH | 1 |
| Wachtel, AE | 1 |
| Basharova, EV | 1 |
| Chasen, M | 1 |
| Powers, D | 1 |
| Navari, R | 4 |
| Schnadig, I | 1 |
| Shi, Q | 1 |
| Li, W | 1 |
| Li, H | 1 |
| Le, Q | 1 |
| Liu, S | 1 |
| Zong, S | 1 |
| Zheng, L | 1 |
| Hou, F | 1 |
| Simino, GP | 1 |
| Marra, LP | 1 |
| Andrade, EI | 1 |
| Acúrcio, Fde A | 1 |
| Reis, IA | 1 |
| De Araújo, VE | 1 |
| Cherchiglia, ML | 1 |
| Kim, JE | 1 |
| Kim, JW | 1 |
| Sung, YL | 1 |
| Cho, CH | 1 |
| Lee, MA | 1 |
| Kim, DJ | 1 |
| Ahn, MJ | 2 |
| Lee, KY | 1 |
| Sym, SJ | 1 |
| Lim, MC | 1 |
| Jung, H | 1 |
| Cho, EK | 1 |
| Min, KW | 1 |
| Okumura, LM | 1 |
| D'Athayde Rodrigues, F | 1 |
| Ferreira, MAP | 1 |
| Moreira, LB | 1 |
| Lajolo, PP | 1 |
| de Camargo, B | 1 |
| del Giglio, A | 2 |
| Pikó, B | 1 |
| Bassam, A | 1 |
| Roila, F | 6 |
| Rolski, J | 1 |
| Ramlau, R | 1 |
| Dediu, M | 1 |
| Russo, MW | 3 |
| Bandekar, RR | 1 |
| Grunberg, SM | 6 |
| Boice, JA | 1 |
| Taylor, A | 2 |
| Brown, C | 1 |
| Hardwick, JS | 1 |
| Carides, A | 1 |
| Webb, T | 1 |
| Schmoll, HJ | 2 |
| Ng, WL | 1 |
| Della-Fiorentina, SA | 1 |
| Apornwirat, W | 1 |
| Shaharyar, A | 1 |
| Aziz, Z | 1 |
| Van Belle, S | 4 |
| Levin, J | 1 |
| Ranganathan, S | 1 |
| Guckert, M | 1 |
| Gridelli, C | 1 |
| Haiderali, AM | 1 |
| Blackburn, LM | 1 |
| Lykopoulos, K | 1 |
| Urien, S | 1 |
| Doz, F | 1 |
| Giraud, C | 1 |
| Rey, E | 1 |
| Gentet, JC | 1 |
| Chastagner, P | 1 |
| Vassal, G | 1 |
| Corradini, N | 1 |
| Auvrignon, A | 1 |
| Leblond, P | 1 |
| Rubie, H | 1 |
| Treluyer, JM | 1 |
| Dandamudi, UB | 1 |
| Adams, LM | 1 |
| Johnson, B | 1 |
| Bauman, J | 1 |
| Morris, S | 1 |
| Murray, S | 1 |
| Webb, RT | 1 |
| Gartner, E | 1 |
| Hohl, R | 1 |
| Lewis, LD | 1 |
| Hesketh, PJ | 8 |
| Warr, DG | 2 |
| Street, JC | 1 |
| Carides, AD | 7 |
| Perwitasari, DA | 1 |
| Wessels, JA | 1 |
| van der Straaten, RJ | 1 |
| Baak-Pablo, RF | 1 |
| Mustofa, M | 1 |
| Hakimi, M | 1 |
| Nortier, JW | 1 |
| Gelderblom, H | 2 |
| Guchelaar, HJ | 1 |
| Shi, X | 1 |
| Liu, ZM | 1 |
| Zhu, XD | 1 |
| Zhang, D | 1 |
| Mita, M | 1 |
| Shapiro, GI | 1 |
| Poon, J | 1 |
| Small, K | 1 |
| Tzontcheva, A | 1 |
| Kantesaria, B | 1 |
| Zhu, Y | 1 |
| Bannerji, R | 1 |
| Statkevich, P | 1 |
| Lichinitser, MR | 1 |
| Garin, AM | 1 |
| Decramer, ML | 1 |
| Riviere, A | 2 |
| Thant, M | 1 |
| Brestan, E | 1 |
| Bui, B | 1 |
| Eldridge, K | 1 |
| De Smet, M | 1 |
| Michiels, N | 1 |
| Reinhardt, RR | 1 |
| Evans, JK | 5 |
| Gertz, BJ | 1 |
| Lachaine, J | 1 |
| Laurier, C | 1 |
| Chawla, SP | 3 |
| Gralla, RJ | 4 |
| Rittenberg, C | 1 |
| Elmer, ME | 2 |
| Schmidt, C | 2 |
| Horgan, KJ | 4 |
| Aapro, M | 1 |
| Tattersall, FD | 1 |
| Naylor, RJ | 1 |
| Hargreaves, R | 1 |
| Tremblay, PB | 2 |
| Kaiser, R | 2 |
| Sezer, O | 2 |
| Rosler, N | 1 |
| Schelenz, C | 2 |
| Possinger, K | 2 |
| Roots, I | 2 |
| Brockmoller, J | 2 |
| Martin, AR | 1 |
| Pearson, JD | 1 |
| Horgan, K | 1 |
| Elmer, M | 1 |
| Cai, B | 1 |
| Streitberger, K | 1 |
| Friedrich-Rust, M | 1 |
| Bardenheuer, H | 1 |
| Unnebrink, K | 1 |
| Windeler, J | 1 |
| Goldschmidt, H | 2 |
| Egerer, G | 2 |
| Xie, XD | 1 |
| Zheng, ZD | 1 |
| Liu, DW | 1 |
| Liu, YY | 1 |
| Shan, XJ | 1 |
| de Wit, R | 3 |
| Ianus, J | 2 |
| Beck, K | 1 |
| Reines, S | 1 |
| Bhatia, A | 2 |
| Tripathi, KD | 2 |
| Sharma, M | 2 |
| Zhang, ZK | 1 |
| Feng, RX | 1 |
| Wang, YL | 1 |
| Tralongo, P | 1 |
| Dimari, A | 1 |
| Conti, G | 1 |
| Aiello, R | 1 |
| Mauceri, G | 1 |
| Goldsmith, B | 1 |
| Corapçioglu, F | 1 |
| Sarper, N | 1 |
| Guoguang-Ma, J | 1 |
| Rubenstein, EB | 1 |
| Olver, IN | 1 |
| Donovan-Rodriguez, T | 1 |
| Urch, CE | 1 |
| Dickenson, AH | 1 |
| Bloch, J | 1 |
| Rixe, O | 1 |
| Meric, JB | 1 |
| Delgado, A | 2 |
| Khayat, D | 1 |
| Pinarli, FG | 1 |
| Elli, M | 1 |
| Dagdemir, A | 1 |
| Baysal, K | 1 |
| Acar, S | 1 |
| Babaoglu, MO | 1 |
| Bayar, B | 1 |
| Aynacioglu, AS | 1 |
| Kerb, R | 1 |
| Abali, H | 1 |
| Celik, I | 1 |
| Bozkurt, A | 1 |
| Khamales, S | 1 |
| Bethune-Volters, A | 1 |
| Chidiac, J | 1 |
| Bensaoula, O | 1 |
| Di Palma, M | 1 |
| Aapro, MS | 1 |
| Poli-Bigelli, S | 1 |
| Kim, HK | 1 |
| Park, K | 1 |
| von Pawel, J | 1 |
| Giezek, H | 1 |
| Ahmed, T | 1 |
| Chan, CY | 1 |
| Llanes, LR | 1 |
| Fassbender, K | 1 |
| Baracos, VE | 1 |
| Watanabe, S | 1 |
| Loos, WJ | 2 |
| Freedman, SJ | 1 |
| Van Dyck, K | 1 |
| Gambale, JJ | 1 |
| Li, S | 1 |
| Murphy, GM | 1 |
| van Noort, C | 1 |
| de Bruijn, P | 1 |
| Verweij, J | 4 |
| Lordick, F | 1 |
| Ehlken, B | 1 |
| Ihbe-Heffinger, A | 1 |
| Berger, K | 1 |
| Krobot, KJ | 1 |
| Pellissier, J | 1 |
| Davies, G | 1 |
| Deuson, R | 1 |
| Shi, Y | 1 |
| He, X | 1 |
| Yang, S | 1 |
| Ai, B | 1 |
| Zhang, C | 1 |
| Huang, D | 1 |
| Dong, M | 1 |
| Liu, P | 1 |
| Zhou, S | 1 |
| Han, X | 1 |
| McNulty, R | 1 |
| Meiri, E | 1 |
| Jhangiani, H | 1 |
| Vredenburgh, JJ | 1 |
| Barbato, LM | 1 |
| Carter, FJ | 1 |
| Yang, HM | 1 |
| Baranowski, V | 1 |
| Kast, RE | 1 |
| Foley, KF | 1 |
| Wilkes, G | 1 |
| Hamadani, M | 1 |
| Chaudhary, L | 1 |
| Awan, FT | 1 |
| Khan, JK | 1 |
| Kojouri, K | 1 |
| Ozer, H | 1 |
| Tfayli, A | 1 |
| Hasler, SB | 1 |
| Hirt, A | 1 |
| Ridolfi Luethy, A | 1 |
| Leibundgut, KK | 1 |
| Ammann, RA | 1 |
| Shelke, AR | 1 |
| Roscoe, JA | 1 |
| Colman, LK | 1 |
| Banerjee, TK | 1 |
| Kirshner, JJ | 1 |
| Dłuzniewska, A | 1 |
| Balwierz, W | 1 |
| Armata, J | 1 |
| Eliasińska, A | 1 |
| Esseboom, EU | 1 |
| Rojer, RA | 1 |
| Borm, JJ | 1 |
| Statius van Eps, LW | 1 |
| Noble, A | 1 |
| Bremer, K | 1 |
| Goedhals, L | 2 |
| Cupissol, D | 1 |
| Dilly, SG | 1 |
| Zhou, J | 1 |
| Zeng, W | 1 |
| Zhang, P | 1 |
| Matera, MG | 1 |
| Di Tullio, M | 1 |
| Lucarelli, C | 1 |
| Casale, F | 1 |
| Calabria, C | 1 |
| Lampa, E | 1 |
| Indolfi, P | 1 |
| Rossi, F | 1 |
| Tsavaris, N | 2 |
| Charalambidis, G | 2 |
| Ganas, N | 1 |
| Pagou, M | 2 |
| Karabellis, A | 1 |
| Mylonakis, N | 2 |
| Benou, N | 1 |
| Tsikalakis, D | 1 |
| Kosmidis, P | 2 |
| Gandara, D | 1 |
| Hesketh, P | 2 |
| Hall, S | 1 |
| Mailliard, J | 1 |
| Ritter, H | 1 |
| Friedman, C | 1 |
| Fitts, D | 1 |
| Marty, M | 2 |
| Kleisbauer, JP | 1 |
| Fournel, P | 1 |
| Vergnenegre, A | 1 |
| Carles, P | 1 |
| Loria-Kanza, Y | 1 |
| Simonetta, C | 1 |
| de Bruijn, KM | 1 |
| Alvarez, O | 1 |
| Freeman, A | 1 |
| Bedros, A | 1 |
| Call, SK | 1 |
| Volsch, J | 1 |
| Kalbermatter, O | 1 |
| Halverson, J | 1 |
| Convy, L | 1 |
| Cook, L | 1 |
| Mick, K | 1 |
| Seliuzhitskiĭ, IV | 1 |
| Eliseev, SN | 1 |
| Ivanov, AI | 1 |
| Hsyu, PH | 1 |
| Pritchard, JF | 3 |
| Bozigian, HP | 1 |
| Gooding, AE | 1 |
| Griffin, RH | 1 |
| Mitchell, R | 1 |
| Bjurstrom, T | 1 |
| Panella, TL | 1 |
| Huang, AT | 1 |
| Hansen, LA | 1 |
| Adenis, A | 1 |
| Bonneterre, J | 1 |
| Karabelis, A | 1 |
| Bacoyiannis, C | 1 |
| Campora, E | 1 |
| Giudici, S | 1 |
| Merlini, L | 1 |
| Rubagotti, A | 1 |
| Rosso, R | 1 |
| Tonato, M | 3 |
| Del Favero, A | 4 |
| Kris, MG | 2 |
| Pisters, KM | 1 |
| Hinkley, L | 1 |
| Ballatori, E | 2 |
| Harvey, WH | 2 |
| Harker, WG | 1 |
| Beck, TM | 3 |
| Ryan, T | 2 |
| Bricker, LJ | 1 |
| Kish, JA | 1 |
| Murphy, WK | 1 |
| Hainsworth, JD | 3 |
| Haley, B | 1 |
| Khoo, KS | 1 |
| Ang, PT | 2 |
| Soh, LT | 1 |
| Au, E | 1 |
| Zoubek, A | 1 |
| Kronberger, M | 1 |
| Puschmann, A | 1 |
| Gadner, H | 1 |
| Ribiero, MM | 1 |
| de Faria, L | 1 |
| dos Reis, F | 1 |
| Fráguas, A | 1 |
| de Matos, E | 1 |
| Uva, S | 1 |
| Ribeiro, I | 1 |
| Brandão, A | 1 |
| Ribeiro, M | 1 |
| Batarda, M | 1 |
| Marschner, N | 2 |
| Cubeddu, LX | 2 |
| Pendergrass, K | 1 |
| York, M | 2 |
| Burton, G | 1 |
| Meshad, M | 2 |
| Galvin, D | 1 |
| Ciociola, AA | 1 |
| Lee, JS | 1 |
| Lee, KH | 1 |
| Suh, C | 1 |
| Choi, SS | 1 |
| Kim, SH | 1 |
| Laplanche, A | 1 |
| Gérondeau, N | 1 |
| Zeng, WY | 1 |
| Priestman, TJ | 2 |
| Roberts, JT | 1 |
| Upadhyaya, BK | 1 |
| Lane, M | 1 |
| Lester, EP | 1 |
| Sridhar, KS | 1 |
| Mortimer, J | 1 |
| Murphy, W | 1 |
| Sanderson, PE | 1 |
| Csáki, C | 1 |
| Ferencz, T | 1 |
| Koós, R | 1 |
| Schuler, D | 1 |
| Borsi, J | 1 |
| Jantunen, IT | 2 |
| Flander, MK | 2 |
| Heikkinen, MI | 1 |
| Kuoppala, TA | 1 |
| Teerenhovi, L | 2 |
| Kataja, VV | 2 |
| Kołecki, P | 1 |
| Wachowiak, J | 1 |
| Beshari, SE | 1 |
| Muhonen, TT | 1 |
| Planting, AS | 1 |
| van der Burg, ME | 1 |
| de Boer-Dennert, M | 1 |
| Stoter, G | 1 |
| Hewitt, M | 1 |
| McQuade, B | 4 |
| Stevens, R | 1 |
| Barbounis, V | 1 |
| Koumakis, G | 1 |
| Vassilomanolakis, M | 1 |
| Hatzichristou, H | 1 |
| Tsousis, S | 1 |
| Efremidis, AP | 1 |
| Koriech, OM | 1 |
| Depierre, A | 3 |
| Kurylak, A | 1 |
| Kurylak, D | 1 |
| Masłowska, E | 1 |
| Gałaj, A | 1 |
| Zawadzka, I | 1 |
| Martoni, A | 1 |
| Angelelli, B | 1 |
| Guaraldi, M | 1 |
| Strocchi, E | 1 |
| Pannuti, F | 1 |
| Grote, T | 1 |
| Gralla, R | 1 |
| Hainsworth, J | 1 |
| Kris, M | 1 |
| Anthony, L | 1 |
| Khojasteh, A | 1 |
| Tapazoglou, E | 1 |
| Benedict, C | 1 |
| Hahne, W | 1 |
| Catimel, G | 1 |
| Droz, JP | 2 |
| du Bois, A | 1 |
| Vach, W | 1 |
| Cramer-Giraud, U | 1 |
| Thomssen, C | 1 |
| Glaubitz, M | 1 |
| Fiola, M | 1 |
| Franzén, L | 1 |
| Nyman, J | 1 |
| Hagberg, H | 1 |
| Jakobsson, M | 1 |
| Sorbe, B | 1 |
| Nyth, AL | 1 |
| Lomberg, H | 1 |
| Henriksson, R | 1 |
| Fauser, AA | 1 |
| Duclos, B | 1 |
| Chemaissani, A | 1 |
| Cognetti, F | 1 |
| Diaz-Rubio, E | 1 |
| Cortes-Funes, H | 1 |
| Conte, PF | 1 |
| Dressler, H | 1 |
| Olver, I | 1 |
| Paska, W | 2 |
| Seitz, JF | 1 |
| Stewart, DJ | 1 |
| McRae, J | 1 |
| Wilkinson, JR | 1 |
| Löffler, TM | 1 |
| Freund, W | 1 |
| Lipke, J | 1 |
| Hausamen, TU | 1 |
| Tyc, VL | 1 |
| Mulhern, RK | 1 |
| Barclay, DR | 1 |
| Smith, BF | 1 |
| Bieberich, AA | 1 |
| Tavorath, R | 1 |
| Currow, DC | 1 |
| Coughlan, M | 1 |
| Fardell, B | 1 |
| Cooney, NJ | 1 |
| Sigsgaard, T | 1 |
| Handberg, J | 1 |
| Schousboe, BM | 1 |
| Hansen, M | 1 |
| Dombernowsky, P | 2 |
| Salwender, H | 1 |
| Kempe, R | 1 |
| Voigt, T | 1 |
| Chang, A | 1 |
| Griffin, D | 1 |
| Wentz, A | 1 |
| Lebeau, B | 1 |
| Giovannini, M | 1 |
| Kaluzinski, L | 1 |
| Votan, B | 1 |
| Hédouin, M | 1 |
| d'Allens, H | 1 |
| Zeidman, A | 1 |
| Ben Dayan, D | 1 |
| Ben Zion, T | 1 |
| Kaufman, O | 1 |
| Cohen, AM | 1 |
| Mittelman, M | 1 |
| Leong, SS | 1 |
| Teo, CP | 1 |
| Tao, M | 1 |
| Carpenter, CE | 1 |
| Weitzel, LC | 1 |
| Johnson, NE | 1 |
| Nash, DB | 1 |
| Berto, P | 1 |
| De Angelis, V | 1 |
| Neri, C | 1 |
| Olivieri, A | 1 |
| Plosker, GL | 1 |
| Milne, RJ | 1 |
| Rough, SS | 1 |
| Carro, GW | 1 |
| Davidson, N | 1 |
| Erikstein, B | 1 |
| L'Esperance, B | 1 |
| Ruff, P | 1 |
| Miller, I | 1 |
| Curtis, P | 2 |
| Edelman, MJ | 1 |
| Gandara, DR | 1 |
| Meyers, FJ | 1 |
| Ishii, R | 1 |
| O'Mahony, M | 1 |
| Uhrich, M | 1 |
| Lauder, I | 1 |
| Houston, J | 1 |
| Gietzen, DW | 1 |
| Needles, B | 1 |
| Miranda, E | 1 |
| Garcia Rodriguez, FM | 1 |
| Diaz, LB | 1 |
| Spector, J | 1 |
| Craig, J | 1 |
| Cohen, G | 1 |
| Krasnow, S | 1 |
| Brogden, J | 1 |
| Ames, M | 1 |
| Safonova, SA | 1 |
| Gershanovich, ML | 1 |
| Punanov, IuA | 1 |
| Kolygin, BA | 1 |
| Castejon, AM | 1 |
| Paez, X | 1 |
| Hernandez, L | 1 |
| Oge, A | 1 |
| Alkiş, N | 1 |
| Oge, O | 1 |
| Kartum, A | 1 |
| de Jonge, MJ | 1 |
| Sparreboom, A | 1 |
| Liaw, CC | 2 |
| Wang, CH | 2 |
| Chang, HK | 2 |
| Kao, CY | 1 |
| Huang, JS | 2 |
| Barrajon, E | 1 |
| de las Peñas, R | 1 |
| White, L | 1 |
| Daly, SA | 1 |
| McKenna, CJ | 1 |
| Zhestkova, N | 1 |
| Leal, C | 1 |
| Breatnach, F | 1 |
| Smelhaus, V | 1 |
| Hung, IJ | 1 |
| Kowalczyk, J | 1 |
| Ninane, J | 1 |
| Mitchell, T | 1 |
| Haigh, C | 1 |
| Soares, HP | 1 |
| Caparroz, C | 1 |
| Castro, PC | 1 |
| Liau, CT | 1 |
| Yeh, KY | 1 |
| Lin, YC | 1 |
| Nishida, T | 1 |
| Yakushiji, M | 1 |
| Ohizumi, K | 1 |
| Noda, S | 1 |
| Rikimaru, T | 1 |
| Matsuoka, K | 1 |
| Watters, J | 1 |
| Riley, M | 1 |
| Pedley, I | 1 |
| Whitehead, A | 1 |
| Overend, M | 1 |
| Goss, I | 1 |
| Allgar, V | 1 |
| Keefe, DL | 1 |
| Hardy, J | 1 |
| Daly, S | 1 |
| Albertsson, M | 1 |
| Chimontsi-Kypriou, V | 1 |
| Stathopoulos, P | 1 |
| Bernstein, BJ | 1 |
| Ong, C | 1 |
| Papies, A | 1 |
| Bauer, S | 1 |
| Enghofer, E | 1 |
| Parr, MD | 1 |
| McIntyre, WJ | 1 |
| Henderson, LM | 1 |
| MacDonald, JS | 1 |
| Chandler, MH | 1 |
| Ballard, HS | 1 |
| Bottino, G | 1 |
| Bottino, J | 1 |
| Palmer, JB | 1 |
| Greenstreet, YL | 1 |
| Seynaeve, C | 2 |
| Schuller, J | 1 |
| Buser, K | 1 |
| Porteder, H | 1 |
| Sevelda, P | 1 |
| Christmann, D | 1 |
| Schmidt, M | 1 |
| Kitchener, H | 1 |
| Paes, D | 1 |
| Fraschini, G | 1 |
| Graves, T | 1 |
| Suminaga, M | 3 |
| Furue, H | 3 |
| Taguchi, T | 3 |
| Niitani, H | 3 |
| Ota, K | 3 |
| Tsukagoshi, S | 3 |
| Ariyoshi, Y | 3 |
| Ikeda, M | 3 |
| Akasaka, Y | 3 |
| Ohta, J | 3 |
| Jürgens, H | 1 |
| Dicato, MA | 1 |
| Freeman, AJ | 1 |
| Wells, CD | 1 |
| Coates, AS | 1 |
| Childs, A | 1 |
| Cox, K | 1 |
| Forsyth, C | 1 |
| Joshua, DE | 1 |
| McNeil, E | 1 |
| Grygiel, JJ | 1 |
| Castle, WM | 1 |
| Cunningham, K | 1 |
| Kanarek, BB | 1 |
| Buxton, MJ | 1 |
| O'Brien, BJ | 1 |
| Beyer, JH | 1 |
| Räth, U | 1 |
| Souchon, R | 1 |
| Berry, WR | 1 |
| House, KW | 1 |
| Lee, JT | 1 |
| Plagge, PB | 1 |
| Meshad, MW | 1 |
| Grapski, R | 1 |
| Egan, AP | 1 |
| Taggart, JR | 1 |
| Bender, CM | 1 |
| Ersbøll, J | 1 |
| de Mulder, PH | 1 |
| Lane-Allman, E | 1 |
| van Liessum, PA | 1 |
| Einhorn, LH | 1 |
| Nagy, C | 1 |
| Werner, K | 1 |
| Finn, AL | 1 |
| Lazarus, HM | 1 |
| Bryson, JC | 1 |
| Lemon, E | 1 |
| Blumer, J | 1 |
| Serve, H | 1 |
| Perker, M | 1 |
| Ertl, A | 1 |
| Reichold, M | 1 |
| Fink, U | 1 |
| Berdel, WE | 1 |
| Pouillart, P | 1 |
| Paule, B | 1 |
| Brion, N | 1 |
| Bons, J | 1 |
| Tucker, ML | 1 |
| Jackson, MR | 1 |
| Scales, MD | 1 |
| Spurling, NW | 1 |
| Tweats, DJ | 1 |
| Capel-Edwards, K | 1 |
| Clark, RA | 1 |
| Tyson, LB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention [NCT01594749] | Phase 3 | 1,015 participants (Actual) | Interventional | 2012-09-24 | Completed | ||
| A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Ped[NCT01362530] | Phase 3 | 307 participants (Actual) | Interventional | 2011-09-13 | Completed | ||
| A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC o[NCT01442376] | Phase 3 | 502 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| A Korean Multicenter, Randomized, Double-Blind, Clinical Trial to Evaluate the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapies (MEC, Non-AC R[NCT01636947] | Phase 4 | 494 participants (Actual) | Interventional | 2012-12-12 | Completed | ||
| A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Moderately Emetoge[NCT00337727] | Phase 3 | 848 participants (Actual) | Interventional | 2007-01-01 | Completed | ||
| A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist Casopitant (GW679769) in Combination With Ondansetron a[NCT00366834] | Phase 3 | 1,840 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| A Phase I, Open-Label, Randomized, Two Period Crossover Study to Investigate the Effects of GW679769 on the Pharmacokinetics of Docetaxel in Subjects With Cancer[NCT00440128] | Phase 1 | 12 participants (Actual) | Interventional | 2007-05-04 | Completed | ||
| A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Cyclin-Dependent Kinase (CDK) Inhibitor SCH 727965 Administered Every 3 Weeks in Subjects With Advanced Malignancies[NCT00871910] | Phase 1 | 81 participants (Actual) | Interventional | 2006-10-11 | Completed | ||
| Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis: a Double-blind Randomized Trial[NCT00869310] | Phase 3 | 303 participants (Actual) | Interventional | 2009-09-30 | Terminated (stopped due to we terminated the study before enrolling 303/560 due to a slow accrual) | ||
| Evaluation of Dyspeptic Symptoms in Oncological Frail Patients With Extraintestinal Cancer in Chemotherapy. Assessment of Circulating Levels of Glucagon-like Peptide 2 (GLP-2) in Relation to Mucositis[NCT01382667] | 70 participants (Actual) | Observational | 2011-07-31 | Completed | |||
| The Effects of Intravenous Fosaprepitant and Ondansetron for the Prevention of Postoperative Nausea and Vomiting in Thoracicsurgery Patients: A Single-center, Randomized, Double-Blinded Clinical Study[NCT05881486] | 234 participants (Anticipated) | Interventional | 2023-06-30 | Not yet recruiting | |||
| Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting---A Randomized Single Center Phase III Trial[NCT02484911] | Phase 3 | 120 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| Observational Study of Delayed Nausea and Vomiting Following Administration of Carboplatin Containing Regimens for Treatment of Cancer[NCT00696280] | 106 participants (Actual) | Observational | 2006-11-30 | Completed | |||
| A Phase III Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer Receiving 5-day Cisplatin C[NCT05244577] | Phase 3 | 75 participants (Anticipated) | Interventional | 2022-01-18 | Recruiting | ||
| Pain Phenotyping of Patients With Bone Cancer Pain[NCT03908853] | 70 participants (Anticipated) | Observational | 2019-02-05 | Recruiting | |||
| A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Safety, Tolerability and Efficacy of Aprepitant Regimen Compared to Ondansetron Regimen for the Prevention of Chemotherapy Induced Nausea and Vo[NCT00090207] | Phase 4 | 477 participants (Actual) | Interventional | 2004-01-13 | Completed | ||
| The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis[NCT04169828] | 176 participants (Anticipated) | Interventional | 2019-08-02 | Recruiting | |||
| 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence[NCT01549652] | 133 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| Antagonism Research Between Antiemetics Agents (Droperidol, Dexametasone, Ondansetron) and Acetaminophen in Thyroidectomy's Post-operative Analgesia.[NCT01679093] | Phase 3 | 66 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.[NCT03606369] | Phase 2/Phase 3 | 560 participants (Anticipated) | Interventional | 2015-11-05 | Recruiting | ||
| IRB-HSR# 14583: Intravenous Ondansetron to Attenuate the Hypotensive, Bradycardic Response to Spinal Anesthesia in Healthy Parturients[NCT01414777] | Phase 2/Phase 3 | 68 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A Complete Response was defined as no vomiting and no use of rescue medication. (NCT01594749)
Timeframe: 0 to 120 hours after initiation of MEC
| Intervention | Percentage of Participants (Number) |
|---|---|
| Fosaprepitant Regimen | 77.1 |
| Control Regimen | 66.9 |
A Complete Response was defined as no vomiting and no use of rescue medication. (NCT01594749)
Timeframe: 0 to 24 hours after initiation of MEC
| Intervention | Percentage of Participants (Number) |
|---|---|
| Fosaprepitant Regimen | 93.2 |
| Control Regimen | 91.0 |
A Complete Response was defined as no vomiting and no use of rescue medication. (NCT01594749)
Timeframe: 25 to 120 hours after initiation of MEC
| Intervention | Percentage of Participants (Number) |
|---|---|
| Fosaprepitant Regimen | 78.9 |
| Control Regimen | 68.5 |
The percentages of participants with infusion-site thrombophlebitis are presented. Thrombophlebitis was defined as a condition affecting a superficial vein used for an IV infusion, associated with red color, hardness upon palpation, and the presence of a tender cord and possible fever. (NCT01594749)
Timeframe: Day 1 through Day 17, inclusive
| Intervention | Percentage of Participants (Number) |
|---|---|
| Fosaprepitant Regimen | 0.6 |
| Control Regimen | 0.0 |
No Vomiting was defined as no emetic (vomiting) episodes, including no vomiting and no retching or dry heaves (attempts to vomit that are not productive of stomach contents), regardless of use of rescue medication. (NCT01594749)
Timeframe: 0 to 120 hours after initiation of MEC
| Intervention | Percentage of participants (Number) |
|---|---|
| Fosaprepitant Regimen | 82.7 |
| Control Regimen | 72.9 |
The percentages of participants with severe infusion-site reactions, including severe site pain, or severe site redness (erythema) or severe site hardness (induration) are presented. (NCT01594749)
Timeframe: Day 1 through Day 17, inclusive
| Intervention | Percentage of Participants (Number) |
|---|---|
| Fosaprepitant Regimen | 0.0 |
| Control Regimen | 0.0 |
Acute phase was defined as 0 to 24 hours after the start of chemotherapy. Complete response was defined as no vomiting or retching and no use of rescue medication in the acute phase of Cycle 1. (NCT01362530)
Timeframe: 0 to 24 hours after initiation of chemotherapy
| Intervention | Percentage of participants (Number) |
|---|---|
| Aprepitant Regimen | 66.4 |
| Control Regimen | 52.0 |
Delayed Phase was defined as 25-120 hours after the start of chemotherapy. Complete response was defined as no vomiting or retching and no use of rescue medication in the delayed phase of Cycle 1. (NCT01362530)
Timeframe: 25 to 120 hours after the start of chemotherapy
| Intervention | Percentage of participants (Number) |
|---|---|
| Aprepitant Regimen | 50.7 |
| Control Regimen | 26.0 |
Overall phase was defined as 0 to 120 hourse after the start of chemotherapy. Complete response was defined as no vomiting or retching and no use of rescue medication in the overall phase of Cycle 1. (NCT01362530)
Timeframe: 0 to 120 hours after initiation of chemotherapy
| Intervention | Percentage of participants (Number) |
|---|---|
| Aprepitant Regimen | 40.1 |
| Control Regimen | 20.0 |
Overall phase was defined as 0 to 120 hourse after the start of chemotherapy. No vomiting was defined as no emesis or retching or dry heaves in the overall phase of Cycle 1. (NCT01362530)
Timeframe: 0 to 120 hours after initiation of chemotherapy
| Intervention | Percentage of participants (Number) |
|---|---|
| Aprepitant Regimen | 46.7 |
| Control Regimen | 21.3 |
Complete Response (CR) was defined as no vomiting, no retching, and no use of antiemetic rescue medication from >24 to 120 hours (delayed phase) after T0 (start of administration of the most emetogenic chemotherapy) during first cycle. (NCT01442376)
Timeframe: from >24 to 120 hours (delayed phase) after T0
| Intervention | percentage of patients (Number) |
|---|---|
| Palonosetron 10 mcg/kg | 28.9 |
| Palonosetron 20 mcg/kg | 38.8 |
| Ondansetron | 28.4 |
Complete Response (CR) was defined as no vomiting, no retching, and no use of antiemetic rescue medication from 0 to 24 hours (acute phase) after T0 (start of administration of the most emetogenic chemotherapy) during first cycle. Time 0 (T0) is defined as the time when the patient starts the first cycle of chemotherapy. (NCT01442376)
Timeframe: 0 to 24 hours after T0
| Intervention | percentage of patients (Number) |
|---|---|
| Palonosetron 10 mcg/kg | 54.2 |
| Palonosetron 20 mcg/kg | 59.4 |
| Ondansetron | 58.6 |
The number of emetic events that occurred during the Overall Stage (0 to 120 hours after initiation of MEC) are presented. (NCT01636947)
Timeframe: Hour 0 on Day 1 to Day 5 (approximately 120 hours)
| Intervention | Number of Emetic Events (Number) |
|---|---|
| Aprepitant Regimen | 54 |
| Control Regimen | 68 |
"The Functional Living Index-Emesis questionnaire (FLIE) is a validated, participant-reported instrument to measure the impact of chemotherapy-induced nausea and vomiting on daily life. There are 9 nausea-related items and 9 vomiting-related items, each on a 7-point scale. For the purposes of this study, No Impact on daily life was defined as an average item score of >6 on the 7-point scale; a total score >108 indicates no impact on daily life. Overall Stage=0 to 120 hours after initiation of MEC." (NCT01636947)
Timeframe: Day 6
| Intervention | Percentage of Participants (Number) |
|---|---|
| Aprepitant Regimen | 76.8 |
| Control Regimen | 73.8 |
"Nausea was to be assessed using a 100-mm horizontal visual analogue scale (VAS) located in the participant diary labeled: How much nausea have you had over the last 24 hours? The left end of the scale (0 mm) was labeled no nausea, and the right end of the scale (100 mm) is labeled nausea as bad as it could be. In this study, No Significant Nausea was defined as a VAS nausea rating <25 mm." (NCT01636947)
Timeframe: Days 1 to Day 5
| Intervention | Percentage of Participants (Number) |
|---|---|
| Aprepitant Regimen | 76.4 |
| Control Regimen | 72.4 |
An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the study drug. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition, which is temporally associated with the use of the study drug, is also an adverse event. Nausea and vomiting experienced during Days 1-6 were not counted as adverse events unless they were reported as a serious adverse event. (NCT01636947)
Timeframe: Day 1 through Day 29 (Up to 28 days after first dose of study drug)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Aprepitant Regimen | 56.2 |
| Control Regimen | 53.2 |
A vomiting episode was defined as one or more episodes of emesis (expulsion of stomach contents through the mouth) or retches (an attempt to vomit that is not productive of stomach contents). No vomiting during the Overall Stage was defined as no episodes of emesis during the 120 hours (Days 1-5) after initiation of moderately emetogenic chemotherapy (MEC). (NCT01636947)
Timeframe: Hour 0 on Day 1 to Day 5 (approximately 120 hours)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Aprepitant Regimen | 77.2 |
| Control Regimen | 72.0 |
The percentage of participants who used no rescue therapy after initiation of MEC is presented for the Overall, Acute and Delayed Stages. Overall Stage=0 to 120 hours after initiation of MEC. Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC. (NCT01636947)
Timeframe: Day 1 to Day 5
| Intervention | Percentage of Participants (Number) | ||
|---|---|---|---|
| Overall Stage | Acute Stage | Delayed Stage | |
| Aprepitant Regimen | 84.8 | 98.7 | 84.8 |
| Control Regimen | 87.7 | 99.2 | 88.5 |
A Complete Response was defined as no vomiting or dry heaves and no use of a rescue therapy. Overall Stage=0 to 120 hours after initiation of MEC. Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC. (NCT01636947)
Timeframe: Hour 0 on Day 1 to Day 5 (approximately 120 hours)
| Intervention | Percentage of Participants (Number) | ||
|---|---|---|---|
| Overall Stage | Acute Stage | Delayed Stage | |
| Aprepitant Regimen | 73.4 | 95.8 | 74.3 |
| Control Regimen | 70.4 | 97.9 | 71.2 |
A vomiting episode was defined as one or more episodes of emesis (expulsion of stomach contents through the mouth) or retches (an attempt to vomit that is not productive of stomach contents). Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC. (NCT01636947)
Timeframe: Day 1, Day 2 to Day 5
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Acute Stage | Delayed Stage | |
| Aprepitant Regimen | 95.8 | 78.5 |
| Control Regimen | 98.8 | 72.4 |
The number of patients who reported Complete Response (no vomiting and no use of rescue medication) in the overall phase in Cycle 1. (NCT00337727)
Timeframe: Overall phase (0-120 hours post initiation of MEC) in Cycle 1
| Intervention | Participants (Number) |
|---|---|
| Aprepitant Regimen | 292 |
| Standard Regimen | 229 |
"The number of patients who reported No Vomiting in the overall phase in Cycle~1" (NCT00337727)
Timeframe: Overall phase (0-120 hours post initiation of MEC) in Cycle 1.
| Intervention | Participants (Number) |
|---|---|
| Aprepitant Regimen | 324 |
| Standard Regimen | 252 |
"Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 0 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 20 |
| Control Regimen | 15 |
Acute phase was defined as 0 to 24 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy. (NCT02484911)
Timeframe: 0 to 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 20 |
| Control Regimen | 17 |
"Delayed phase was defined as 24 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 24 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 20 |
| Aprepitant Regimen | 15 |
"Overall Phase was defined as 0 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue ）" (NCT02484911)
Timeframe: 0 to 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 18 |
| Control Regimen | 15 |
"Overall Phase was defined as 24 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 24 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 17 |
| Control Regimen | 7 |
"Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 0 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 17 |
| Control Regimen | 6 |
"Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 0 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 36 |
| Control Regimen | 40 |
Acute phase was defined as 0 to 24 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy. (NCT02484911)
Timeframe: 0 to 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 36 |
| Control Regimen | 41 |
"Delayed phase was defined as 24 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT02484911)
Timeframe: 24 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 36 |
| Control Regimen | 40 |
"Overall Phase was defined as 0 to 24 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 0 to 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 35 |
| Control Regimen | 40 |
"Overall Phase was defined as 24 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 24 to 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 30 |
| Control Regimen | 31 |
"Overall Phase was defined as 0 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT02484911)
Timeframe: 0-120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Olanzapine Regimen | 30 |
| Control Regimen | 30 |
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -0.44 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.68 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.59 |
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in BDIS (Ondansetron) | Change in BDIS (Placebo) | |
| Prevention of Physical Dependence | -0.6 | 0.2 |
"Originally developed by Handelsman, the Objective Opioid Withdrawal Scale (OOWS) score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The minimum score of 0 means the patient is not showing any signs of opioid withdrawal. The maximum score of 13 signifies all signs of opioid withdrawal to the largest extent possible.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If deemed necessary by the clinician, participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 3.6 | 3.6 |
"Originally developed by Handelsman, the OOWS score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The maximum score is 13 and suggests the patient is showing all signs of opioid withdrawal to the largest extent possible. The minimum score of 0 suggests the patient is not showing any signs of opioid withdrawal.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Physical Dependence | 4.5 | 4.2 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in VAS Score (Ondansetron) | Change in VAS Score (Placebo) | |
| Prevention of Physical Dependence | -2.9 | -2.8 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in RMDI (Ondansetron) | Change in RMDI (Placebo) | |
| Prevention of Physical Dependence | -4.6 | -2.0 |
The Subjective Opioid Withdrawal Score (SOWS) score is calculated as the sum of 16 subjective patient-reported symptom scores rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 12.5 | 12.2 |
The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Physical Dependence | 16.4 | 12.0 |
Profile of Mood States (POMS) is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS Score (Ondansetron) | Change in POMS Score (Placebo) | |
| Prevention of Opioid Withdrawal | 29.3 | 28.3 |
(Profile of Mood States) POMS is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS (Ondansetron) | Change in POMS (Placebo) | |
| Prevention of Physical Dependence | 36.1 | 29.2 |
28 reviews available for ondansetron and Benign Neoplasms
| Article | Year |
|---|---|
Evolution of antiemetic studies for radiation-induced nausea and vomiting within an outpatient palliative radiotherapy clinic.
Topics: Adult; Ambulatory Care Facilities; Antiemetics; Humans; Medical Oncology; Middle Aged; Nausea; Neopl | 2019 |
5-Hydroxytryptamine3 receptor antagonists and cardiac side effects.
Topics: Aged; Antiemetics; Antineoplastic Agents; Cardiovascular Diseases; Granisetron; Humans; Isoquinoline | 2014 |
Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; D | 2016 |
Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis.
Topics: Antiemetics; Antineoplastic Agents; Humans; Nausea; Neoplasms; Ondansetron; Quality of Life; Randomi | 2016 |
Aprepitant in pediatric patients using moderate and highly emetogenic protocols: a systematic review and meta-analyses of randomized controlled trials.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Aprepitant; Child; Child, Preschool; Dexamethasone; | 2017 |
[Treatment of tumor therapy-induced nausea and vomiting].
Topics: Anti-Anxiety Agents; Antiemetics; Antineoplastic Agents; Aprepitant; Drug Therapy, Combination; Huma | 2009 |
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Clinical Trials, Phase II as Topic; Drug | 2003 |
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Clinical Trials, Phase II as Topic; Drug | 2003 |
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Clinical Trials, Phase II as Topic; Drug | 2003 |
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Clinical Trials, Phase II as Topic; Drug | 2003 |
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Clinical Trials, Phase II as Topic; Drug | 2003 |
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Clinical Trials, Phase II as Topic; Drug | 2003 |
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Clinical Trials, Phase II as Topic; Drug | 2003 |
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Clinical Trials, Phase II as Topic; Drug | 2003 |
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Clinical Trials, Phase II as Topic; Drug | 2003 |
First choice for radiation-induced nausea and vomiting--the efficacy and safety of granisetron.
Topics: Age Factors; Aged; Antiemetics; Drug Resistance; Granisetron; Humans; Nausea; Neoplasms; Ondansetron | 2004 |
Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Topics: Acute Disease; Adult; Aged; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Cytochrome | 2004 |
Update on anti-emetics for chemotherapy-induced emesis.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Australia; Dose-R | 2005 |
Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Clinical Trials, | 2007 |
Are there differences among the serotonin antagonists?
Topics: Animals; Antiemetics; Cisplatin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Granise | 1994 |
Delayed emesis following anticancer chemotherapy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Dexamethasone; Huma | 1994 |
Antiemetics in cancer chemotherapy: historical perspective and current state of the art.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Humans; Nausea; Neoplasms; Ondansetron | 1994 |
Ondansetron in the control of chemotherapy-induced and radiotherapy-induced emesis in children with malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; Drug Ev | 1993 |
Ondansetron in the treatment of nausea and vomiting. Introduction.
Topics: Antineoplastic Agents; Dexamethasone; Double-Blind Method; Drug Evaluation; Drug Therapy, Combinatio | 1993 |
[Role of ondansetron in oncology].
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Dose-Response Relationship, Drug; Drug | 1993 |
[Use of ondansetron, a 5-HT3 receptor antagonist, as a new type of antiemetic in pediatric oncology].
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Humans; Infant; Neoplasms; | 1993 |
[Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Drug Administ | 1996 |
Drug treatment of chemotherapy-induced delayed emesis.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Humans; Metoclopramide; Nausea; Neopla | 1996 |
Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.
Topics: Costs and Cost Analysis; Drug Therapy; Drug Tolerance; Economics, Pharmaceutical; Forecasting; Formu | 1992 |
Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials.
Topics: Antiemetics; Antineoplastic Agents; Cross-Over Studies; Granisetron; Humans; Nausea; Neoplasms; Onda | 2000 |
The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Interactions; Electrocardiog | 2002 |
Antiemetic activity of ondansetron in cancer patients receiving non-cisplatin chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Humans; Imidazoles; Neoplasms; Ondansetron; Serotonin | 1992 |
The use of ondansetron in patients receiving multiple-day cisplatin regimens.
Topics: Adult; Antiemetics; Cisplatin; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middl | 1992 |
Emesis as a complication of cancer chemotherapy: pathophysiology, importance, and treatment.
Topics: Antiemetics; Antineoplastic Agents; Autonomic Nervous System; Humans; Imidazoles; Nausea; Neoplasms; | 1992 |
Experience with ondansetron in chemotherapy- and radiotherapy-induced emesis.
Topics: Antineoplastic Agents; Humans; Neoplasms; Ondansetron; Radiotherapy; Vomiting | 1992 |
[5-HT3 antagonists in therapy of cystostatic drug-induced vomiting].
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Humans; Neoplasms; Ondansetron; Vomiting | 1992 |
111 trials available for ondansetron and Benign Neoplasms
| Article | Year |
|---|---|
Efficacy and Safety of Olanzapine in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double-blind Placebo-controlled Phase 3 Trial.
Topics: Antiemetics; Antineoplastic Agents; Child; Dexamethasone; Double-Blind Method; Humans; Nausea; Neopl | 2022 |
Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Chemopreventio | 2020 |
Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study.
Topics: Anti-Inflammatory Agents; Antiemetics; Antineoplastic Agents; Dexamethasone; Dose-Response Relations | 2021 |
Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Humans; Infant; Infant, New | 2017 |
Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Dexamethasone; Double-Blind Method; Female; Humans | 2018 |
A randomized, open-label non-inferiority study to compare palonosetron and ondansetron for prevention of acute chemotherapy-induced vomiting in children with cancer receiving moderate or high emetogenic chemotherapy.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Double-Blind Method; Female; Humans; Male; Nausea; | 2018 |
Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophospham | 2018 |
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in paediatric subjects: An analysis by age group.
Topics: Adolescent; Age Factors; Antiemetics; Antineoplastic Agents; Aprepitant; Child; Child, Preschool; Do | 2018 |
Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antiemetics; Antineoplastic Combined Chemo | 2019 |
Palonosetron is a Better Choice Compared With Ondansetron for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in a Resource-limited Pediatric Oncology Center: Results From a Randomized Control Trial.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Male; Nause | 2019 |
Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).
Topics: Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Granisetron; Humans; Indoles; Isoqu | 2014 |
Safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric patients: a prospective, observational study.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Body Weight; Ch | 2014 |
Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial.
Topics: Administration, Intravenous; Adolescent; Anti-Inflammatory Agents; Antiemetics; Aprepitant; Child; C | 2015 |
Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Dexamethasone; Double-Blind Method | 2015 |
[Optimization of pharmacological therapy for weakness syndrome in incurable patients].
Topics: Acetamides; Adamantane; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Ant | 2015 |
Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Benzimidazoles; Dexam | 2015 |
Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Confidence Intervals; Dose- | 2016 |
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemother | 2016 |
Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepit | 2017 |
Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost Savings; Dexamethasone; | 2009 |
Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; | 2009 |
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Double-Blind Method; Dru | 2010 |
Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Topics: Administration, Oral; Alopecia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Brea | 2009 |
Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy.
Topics: Activities of Daily Living; Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antin | 2010 |
Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transp | 2011 |
Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer.
Topics: Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Area Under Curve; Cross-Over Studies; C | 2011 |
Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; D | 2011 |
[Treatment of vomiting in children patients with solid tumor by hewei zhiou recipe combined ondansetron hydrochloride].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Drugs, Chinese | 2012 |
Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Antiemetics; Antineoplastic Agents; Aprepit | 2012 |
Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; D | 2002 |
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Doub | 2003 |
Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplati | 2003 |
Effect of acupuncture compared with placebo-acupuncture at P6 as additional antiemetic prophylaxis in high-dose chemotherapy and autologous peripheral blood stem cell transplantation: a randomized controlled single-blind trial.
Topics: Acupuncture; Adult; Aged; Antiemetics; Combined Modality Therapy; Female; Humans; Male; Middle Aged; | 2003 |
[Effects of Nasea on prevention of gastrointestinal side effects caused by chemotherapeutic drugs].
Topics: Adult; Aged; Anorexia; Antiemetics; Antineoplastic Agents; Benzimidazoles; Female; Gastrointestinal | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 2003 |
Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Female; Humans; Male; Met | 2003 |
Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis.
Topics: Adult; Antiemetics; Cisplatin; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combin | 2004 |
A prospective randomized trial of the antiemetic efficacy and cost-effectiveness of intravenous and orally disintegrating tablet of ondansetron in children with cancer.
Topics: Administration, Oral; Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Cost- | 2005 |
Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomize
Topics: Adrenal Cortex Hormones; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cross-Over Studies; Drug Therapy, Combination; Fema | 2005 |
Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presch | 2006 |
Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporter | 2005 |
A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis.
Topics: Administration, Sublingual; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Double-Blin | 2006 |
Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2006 |
Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2006 |
Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2006 |
Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexametha | 2006 |
Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study.
Topics: Adolescent; Adult; Aged; Anorexia; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benz | 2007 |
Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Dose-Respon | 2007 |
Effect of a nausea expectancy manipulation on chemotherapy-induced nausea: a university of Rochester cancer center community clinical oncology program study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Attitude to Health; Community Health Services; Fema | 2008 |
Prophylaxis of delayed nausea and vomiting after cancer chemotherapy.
Topics: Adult; Aged; Chi-Square Distribution; Cisplatin; Domperidone; Double-Blind Method; Female; Humans; M | 1995 |
A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. The Granisetron Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Double-Blind Method; Female; Granise | 1994 |
[The role of ondansetron (qi lu) in the prevention of cisplatin-induced vomiting--a randomized clinical trial].
Topics: Adolescent; Adult; Aged; Child; China; Cisplatin; Cross-Over Studies; Female; Humans; Male; Middle A | 1995 |
Ondansetron versus metoclopramide as antiemetic treatment during cisplatin-based chemotherapy. A prospective study with special regard to regard to electrolyte imbalance.
Topics: Adult; Aged; Cisplatin; Drug Therapy, Combination; Female; Humans; Male; Metoclopramide; Middle Aged | 1995 |
Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Double-Bl | 1995 |
Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? The French Navoban Study Group.
Topics: Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Indoles; Male; Middle Aged; Nausea; Neo | 1995 |
Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cr | 1995 |
Oral ondansetron pharmacokinetics: the effect of chemotherapy.
Topics: Administration, Oral; Adolescent; Adult; Biological Availability; Cisplatin; Female; Fluorouracil; H | 1994 |
Are 5-hydroxytryptamine-3 receptor antagonists efficient antiemetics for chemotherapy-induced delayed emesis and do they remain effective over subsequent cycles?
Topics: Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Humans; Neoplasms; Ondansetron; Vom | 1994 |
Comparison of ondansentron (GR 38032F) versus ondansentron plus alprazolam as antiemetic prophylaxis during cisplatin-containing chemotherapy.
Topics: Adult; Aged; Alprazolam; Cisplatin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Na | 1994 |
Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses
Topics: Acute Disease; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclophosph | 1994 |
A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis.
Topics: Adult; Aged; Aged, 80 and over; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combina | 1994 |
Use of oral and intravenous ondansetron in patients treated with cisplatin.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cisplatin; Female; Humans; Infusions, Intravenous; Ma | 1993 |
Ondansetron in the treatment of nausea and vomiting induced by chemotherapy. Portuguese Ondansetron Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Nausea; Neopla | 1993 |
Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 1994 |
A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Human | 1994 |
A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; Neop | 1993 |
Randomized double-blind comparison of three dose levels of intravenous ondansetron in the prevention of cisplatin-induced emesis.
Topics: Adult; Aged; Cisplatin; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Double-B | 1993 |
Comparison of ondansetron with customary treatment in the prophylaxis of nausea and emesis induced by non-cisplatin containing chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; | 1993 |
5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy--a randomised study.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Female; Granisetron; Humans; Ind | 1993 |
Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours.
Topics: Adult; Aged; Cisplatin; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Middle Aged; | 1993 |
The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children.
Topics: Antineoplastic Agents; Child; Cisplatin; Female; Humans; Ifosfamide; Male; Nausea; Neoplasms; Ondans | 1993 |
A phase II study of ondansetron as antiemetic prophylaxis in patients receiving high-dose polychemotherapy and stem cell transplantation.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Constipation; Female | 1995 |
[Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Drug Administ | 1996 |
An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens.
Topics: Acute Disease; Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Cross-Over Studies; Femal | 1996 |
Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis P
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Indoles | 1996 |
Pattern of carboplatin-induced emesis. The German Ondansetron Study Group.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Carboplatin; Clinical Protocols; Cyclop | 1995 |
A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy.
Topics: Abdomen; Adult; Aged; Antiemetics; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; N | 1996 |
Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group.
Topics: Adult; Aged; Analysis of Variance; Antiemetics; Antineoplastic Agents; Dose-Response Relationship, D | 1996 |
A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Double | 1996 |
Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial.
Topics: Adult; Aged; Anti-Allergic Agents; Antiemetics; Antineoplastic Agents, Phytogenic; Cimetidine; Clema | 1996 |
Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carboplatin; Cisplatin; Double-Blind Method; Drug T | 1997 |
Comparison of oral itasetron with oral ondansetron: results of a double-blind, active-controlled phase II study in chemotherapy-naive patients receiving moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzimidazoles; Biological Availability; Bridged Bi | 1997 |
Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemother | 1997 |
The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French Ondansetron Study Group.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Double-Blind Method; Drug Th | 1997 |
Granisetron and ondansetron for chemotherapy-related nausea and vomiting.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Female; Granisetron; Humans; Male; Midd | 1998 |
Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: a multicenter, double-masked study. Ondansetron Orally Disintegrating Tablet Emesis Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents, Alkylating | 1999 |
Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome.
Topics: Adult; Aged; Anorexia; Cachexia; Dietary Proteins; Female; Humans; Male; Middle Aged; Neoplasms; Nut | 1999 |
A multicenter, double-blind, randomized comparison of oral ondansetron 8 mg b.i.d., 24 mg q.d., and 32 mg q.d. in the prevention of nausea and vomiting associated with highly emetogenic chemotherapy. S3AA3012 Study Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 1999 |
[Evaluation of the anti-emetic effectiveness of two drug formulations of Ondansetron in combined chemotherapy for children with malignant tumors].
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Pre | 1999 |
Use of intravenous microdialysis to monitor changes in serotonin release and metabolism induced by cisplatin in cancer patients: comparative effects of granisetron and ondansetron.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Female; Granisetron; Humans; Hydroxyindoleacetic Acid | 1999 |
Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin.
Topics: Adult; Antiemetics; Antineoplastic Agents; Cisplatin; Cost-Benefit Analysis; Female; Granisetron; Hu | 2000 |
Topotecan lacks third space sequestration.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve | 2000 |
Control of cisplatin-induced emesis with intravenous ondansetron plus intravenous dexamethasone: a crossover study of triple 8-mg dose of ondansetron.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Cross-Over Studies; Dexamethason | 2000 |
Randomised double blind crossover study comparing ondansetron, granisetron and tropisetron. A cost-benefit analysis.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cost-Benefit Analysis; Cross-Over Studies; Drug Cos | 2000 |
A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherap
Topics: Administration, Oral; Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Dexam | 2000 |
Gender discrepancy observed between chemotherapy-induced emesis and hiccups.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Chi-Square Distribut | 2001 |
[Anti-emetic effects of ondansetron hydrochloride throughout courses of cytotoxic chemotherapy].
Topics: Administration, Oral; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Drug Administration Sched | 2002 |
The development of a protocol for the use of 5-HT3 antagonists in chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical | 2001 |
A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Double-Blind Method; Female; Humans | 2002 |
Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytochrome P-450 CYP2D6; Female; | 2002 |
Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Clinical Protocols; De | 1992 |
Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Stu
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; | 1992 |
[Investigation of anti-emetic effect of ondansetron tablet in multiple doses on nausea and emesis associated with cisplatin].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Cisplatin; Drug Administration Schedule; Female; Hum | 1992 |
[Evaluation of SN-307 (ondansetron), given intravenously for the treatment of nausea and vomiting caused by anticancer drugs including cisplatin-open study].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Drug Administration Schedule; Female; Hu | 1992 |
Ondansetron as prophylaxis for chemotherapy and radiotherapy-induced emesis in children.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Combined Modality Therapy; | 1992 |
[Evaluation of SN-307 (ondansetron), given intravenously in the treatment of nausea and vomiting caused by anticancer drugs including cisplatin--a placebo-controlled, double-blind comparative study].
Topics: Adult; Aged; Cisplatin; Double-Blind Method; Female; Humans; Injections, Intravenous; Male; Middle A | 1992 |
Economic evaluation of ondansetron: preliminary analysis using clinical trial data prior to price setting.
Topics: Adult; Aged; Antineoplastic Agents; Costs and Cost Analysis; Double-Blind Method; Drug Industry; Fem | 1992 |
Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results.
Topics: Cisplatin; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Nausea; Neoplasm | 1992 |
Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Double-Blind Method; Drug Administration Sche | 1992 |
The 5-HT3 receptor antagonist ondansetron re-establishes control in refractory emesis induced by non-cisplatin chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship | 1991 |
Antiemetic efficacy and pharmacokinetic analyses of the serotonin antagonist ondansetron (GR 38032F) during multiple-day chemotherapy with cisplatin prior to autologous bone marrow transplantation.
Topics: Adult; Aged; Antiemetics; Bone Marrow Transplantation; Cisplatin; Combined Modality Therapy; Drug Ad | 1990 |
[Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; H | 1990 |
New antiemetic effective for cisplatin-induced emesis.
Topics: Antiemetics; Cisplatin; Humans; Imidazoles; Multicenter Studies as Topic; Neoplasms; Ondansetron; Qu | 1989 |
55 other studies available for ondansetron and Benign Neoplasms
| Article | Year |
|---|---|
Pharmacogenetic and clinical predictors of ondansetron failure in a diverse pediatric oncology population.
Topics: Antiemetics; Female; Humans; Nausea; Neoplasms; Ondansetron; Pharmacogenetics; Vomiting | 2022 |
Vomiting after intrathecal chemotherapy under anesthesia in pediatric patients with hematologic cancers: A cohort study.
Topics: Anesthesia; Antiemetics; Child; Cohort Studies; Double-Blind Method; Female; Hematologic Neoplasms; | 2024 |
Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Drug | 2020 |
Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Case-Control Studies; Child; Child, Preschool; Feasi | 2019 |
Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QT
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Domperidone; Drug Co | 2021 |
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Therap | 2018 |
Pharmacogenomic potential in advanced cancer patients.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Capecitabine; Drug Prescriptions; Female; Humans; Ma | 2019 |
Postoperative nausea and vomiting in the post-anesthetic care unit, a 5-year survey of a quality assurance program in surgical cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anesthesia Recovery Period; Anesthesiology; Anesthetics; Antiemetics | 2015 |
The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit.
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Dexamethasone; Female; Humans; Incidence; | 2010 |
Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Casse | 2011 |
Cost-efficacy analysis of ondansetron regimens for control of emesis induced by noncisplatin, moderately emetogenic chemotherapy.
Topics: Adrenal Cortex Hormones; Antiemetics; Antineoplastic Agents; Cost-Benefit Analysis; Drug Administrat | 2002 |
Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Female; Gene Deletio | 2003 |
[Current status and direction of researches on antagonizing chemical agents induced vomiting by Chinese and Western medicines].
Topics: Antineoplastic Agents; Drug Therapy, Combination; Drugs, Chinese Herbal; Humans; Neoplasms; Ondanset | 2004 |
Central nervous system side-effects of 5-HT3-receptor antagonists in elderly cancer patients treated with chemotherapy.
Topics: Aged; Antineoplastic Agents; Central Nervous System Diseases; Clinical Trials as Topic; Granisetron; | 2004 |
5HT3-receptor antagonists as antiemetics in cancer.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Granisetron; Humans; Indo | 2005 |
Evidence of a role for descending serotonergic facilitation in a rat model of cancer-induced bone pain.
Topics: Animals; Behavior, Animal; Bone Diseases; Cell Line, Tumor; Disease Models, Animal; Dose-Response Re | 2006 |
[Achieving optimal antiemetic management].
Topics: Antiemetics; Clinical Trials as Topic; Drug Administration Schedule; Humans; Infusions, Intravenous; | 2005 |
Drug utilization review on a tertiary palliative care unit.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Anti-Anxiety Agents; Cost-Benefit Analysis; Drug | 2006 |
Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.
Topics: Antiemetics; Antineoplastic Agents, Phytogenic; Aprepitant; Area Under Curve; Cross-Over Studies; De | 2007 |
Are all 5-HT3 receptor antagonists the same?
Topics: Humans; Indoles; Isoquinolines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinucli | 2007 |
Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects.
Topics: Antiemetics; Antineoplastic Agents; Benzodiazepines; Cachexia; Humans; Mianserin; Mirtazapine; Nause | 2007 |
Antiemetic agents.
Topics: Administration, Oral; Anorexia; Antiemetics; Antineoplastic Agents; Aprepitant; Asthenia; Constipati | 2007 |
Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chem | 2007 |
Safety of ondansetron loading doses in children with cancer.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; | 2008 |
[Evaluation of +ondansetron (Zolfiran) in prevention of vomiting in children treated with cytostatics].
Topics: Adolescent; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Female; Humans | 1995 |
Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Humans; Hydroxyindoleacetic | 1993 |
[The management of vomiting and nausea with zofran during the chemotherapy of malignant tumors].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Feeding an | 1994 |
Oral ondansetron: a useful addition to the supportive care armamentarium?
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Administrati | 1994 |
[Combined use of ondansetron and other anti-emetics to control cisplatin-induced nausea and vomiting].
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Therapy, Combina | 1993 |
Ondansetron as an effective drug in prophylaxis of chemotherapy--induced emesis in children.
Topics: Adolescent; Antineoplastic Agents; Bone Marrow Transplantation; Child; Child, Preschool; Female; Hum | 1993 |
Fluoxetine treatment comprises the antiemetic efficacy of ondansetron in cancer patients.
Topics: Adult; Antiemetics; Binding, Competitive; Female; Fluoxetine; Humans; Male; Middle Aged; Neoplasms; | 1995 |
[Estimation of effectiveness of antiemetic treatment with Zofran given in one dose to children with neoplasms].
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Female; Humans; Infant; Male; Neoplasms; Ondansetr | 1995 |
[Future trends in chemotherapy and impact on the management of emesis].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chronobiology Phenomena; Drug Administr | 1995 |
Controlling the toxicity of palliative radiotherapy: the role of 5-HT3 antagonists.
Topics: Antiemetics; Clinical Trials as Topic; Dopamine Antagonists; Humans; Metoclopramide; Nausea; Neoplas | 1996 |
Variables associated with anticipatory nausea and vomiting in pediatric cancer patients receiving ondansetron antiemetic therapy.
Topics: Adolescent; Antiemetics; Case-Control Studies; Child; Conditioning, Classical; Female; Humans; Male; | 1997 |
Use of ondansetron in palliative medicine.
Topics: Acquired Immunodeficiency Syndrome; Aged; Antiemetics; Female; Humans; Male; Middle Aged; Neoplasms; | 1997 |
Use of ondansetron in the control of emesis in autologous peripheral blood stem cell transplant (APBSCT) for solid tumours.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribut | 1998 |
Cost accounting supports clinical evaluations.
Topics: Academic Medical Centers; Accounting; Cost Allocation; Drug Costs; Drug Utilization Review; Financia | 1994 |
Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy.
Topics: Chemotherapy, Adjuvant; Cisplatin; Costs and Cost Analysis; Dexamethasone; Diphenhydramine; Dose-Res | 1994 |
Developing and implementing oral 5-HT3 receptor antagonist guidelines: a multidisciplinary process.
Topics: Administration, Oral; Antiemetics; Cancer Care Facilities; Female; Hospital Bed Capacity, 300 to 499 | 1998 |
Efficacy of a single 8-mg i.v. dose of ondansetron hydrochloride for preventing chemotherapy-induced emesis.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Female; Humans; Injections, Intr | 2002 |
[Quality of life as a catch phrase and promoter in the pharmaceutical industry].
Topics: Drug Industry; Granulocyte Colony-Stimulating Factor; Humans; Neoplasms; Ondansetron; Quality of Lif | 1992 |
Pharmacokinetics of ondansetron in patients receiving cisplatin therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Male; Middle Aged; Nausea; | 1992 |
Ondansetron and chest pain.
Topics: Aged; Angina Pectoris; Antineoplastic Combined Chemotherapy Protocols; Chest Pain; Female; Humans; M | 1992 |
Ondansetron and chest pain.
Topics: Aged; Angina Pectoris; Antineoplastic Agents; Chest Pain; Humans; Neoplasms; Ondansetron; Product La | 1992 |
Relationships between ondansetron systemic exposure and antiemetic efficacy and safety in cancer patients receiving cisplatin.
Topics: Cisplatin; Humans; Injections, Intravenous; Male; Nausea; Neoplasms; Ondansetron; Safety | 1992 |
Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Female; Humans; Kid | 1992 |
Ondansetron is not associated with vascular adverse events, thrombocytopenia or renal failure.
Topics: Acute Kidney Injury; Cisplatin; Humans; Metoclopramide; Nausea; Neoplasms; Ondansetron; Thrombocytop | 1992 |
Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; Female; Humans; Injections, Intravenous; Male | 1992 |
Management of chemotherapy-related nausea and vomiting using a serotonin antagonist.
Topics: Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Humans; Imidazoles; Nausea; Neoplasms; | 1992 |
[Ondansetron--a 5HT 3 receptor antagonist for the treatment of nausea and vomiting induced by cytostatics and radiotherapy].
Topics: Antiemetics; Antineoplastic Agents; Combined Modality Therapy; Humans; Imidazoles; Nausea; Neoplasms | 1991 |
Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy.
Topics: Adult; Aged; Antiemetics; Cisplatin; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasms; Ondan | 1990 |
GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting.
Topics: Adult; Aged; Cisplatin; Female; Humans; Imidazoles; Male; Middle Aged; Nausea; Neoplasms; Ondansetro | 1989 |
Ondansetron: pre-clinical safety evaluation.
Topics: Administration, Oral; Animals; Dogs; Drug Evaluation, Preclinical; Female; Genes; Guinea Pigs; Imida | 1989 |
Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dos | 1988 |